Document:

Exhibit 10.8 Nu Skin Enterprises Change of Control Severance Plan

NU SKIN ENTERPRISES,
INC. CHANGE OF CONTROL SEVERANCE PLAN FOR ___________________ 

(Effective as of
August 9, 2006) 

NU SKIN ENTERPRISES,
INC. 

CHANGE OF CONTROL
SEVERANCE PLAN FOR ___________________ 

PREAMBLE 

WHEREAS, Nu Skin Enterprises, Inc.
(the “Company”) believes that, in the event it is confronted with a situation
that could result in a change in ownership or control of the Company, continuity of
management will be essential to its ability to evaluate and respond to such a situation in
the best interests of shareholders; 

WHEREAS, the Company also understands that any
such situation will present significant concerns for certain key management personnel at
the Company and designated senior officers of its subsidiaries or other affiliates with
respect to financial and job security; 

WHEREAS, the Company wants to be proactive
in assuring itself and its subsidiaries and affiliates of the services of these critical
individuals during the period in which it is confronting such a situation, and in
providing such individuals with certain financial assurances to enable them to (i) perform
their responsibilities without undue distraction and (ii) exercise their judgment without
bias due to their personal circumstances; 

WHEREAS, the Company wishes to provide
these financial assurances in a uniform and equitable manner without engaging in
negotiations with individual executives. 

NOW, THEREFORE, this Nu Skin Enterprises,
Inc. Change of Control Severance Plan for ___________________ (the “Plan”) is
effective as of August 9, 2006, to provide such assurances for ___________________. 

ARTICLE 1
DEFINITIONS 

1.1        
         "Accrued Obligations"
has the meaning set forth in Section 2.3(a)(iii). 

1.2        
“Affiliate” means any corporation, partnership, limited liability
company, business trust or other entity in which the Company owns, directly or indirectly,
more than 50% of the Voting Power in such entity. 

1.3        
           "Aggregate
Parachute Payments" has the meaning set forth in Section 3.2. 

1.4           “Annual
Compensation” shall mean the sum of (i) Participant’s annual Base Pay, and
(ii) the higher of (A) Participant’s actual annual incentive compensation payment(s)
with respect to services performed in the calendar year prior to Participant’s Year
of Termination, or (B)  Participant’s target bonus the year of Termination; provided, however, that in the case
Participant’s annual compensation for services consists in any material fashion of
commissions and/or other forms of compensation other than Base Pay and annual incentive
pay, the Compensation Committee shall determine the amount of Participant’s Annual
Compensation. 

1.5           “Base
Pay” means Participant’s annual base salary, excluding bonuses, commissions,
incentive and all other remuneration for services rendered to the Company and prior to
reduction for any salary deferrals, including but not limited to, deferrals under plans
established pursuant to Section 125 of the Code or qualified pursuant to Section 401(k) of
the Code. 

1.6                   "Board"
shall mean the Board of Directors of the Company. 

1.7           “Cause”
means any of the following: (1) the Participant’s theft, dishonesty,
misappropriation or conversion of assets or opportunities belonging to the Company or
falsification of any documents or records related to the Company or any of its Affiliates;
(2) the Participant’s improper use or disclosure of the Company’s or any of
its Affiliate’s confidential or proprietary information; (3) any action by the
Participant which has a material detrimental effect on the reputation or business of the
Company or any of its Affiliates including the commission of an act of fraud or
intentional misrepresentation; (4) the Participant’s failure or inability to
perform any reasonable assigned duties, if such failure or inability is reasonably capable
of cure, after being provided with a reasonable opportunity to cure, such failure or
inability; (5) any material breach by the Participant of any employment or service
agreement between the Participant and the Company or any of its Affiliates or applicable
policy of the Company or any of its Affiliates, including any non-disclosure agreement or
other duty of confidentiality or insider trading policy, unless such breach can be cured
and is cured pursuant to the terms of such agreement; (6) breach of any applicable
restrictive covenant evidenced by an agreement between the Participant and the Company or
any Affiliate, including breach of any applicable non-competition or non-solicitation
provision and/or improper disclosure or misuse of any confidential or proprietary
information, or (7) the Participant’s conviction (including any plea of guilty
or nolo contendere) of any criminal act which impairs the Participant’s ability to
perform his or her duties with the Company or any of its Affiliates or conduct related to
the Participant’s service for which either criminal or civil penalties may be sought.
Notwithstanding the foregoing, the definition of “Cause” in an individual
written agreement, other than an individual written agreement for stock awards, between
the Company or any of its Affiliates and the Participant shall supersede the foregoing
definition (it being understood, however, that if no definition of the term Cause is set
forth in such an individual written agreement, the foregoing definition shall apply). 

1.8                   "Change of Control"
shall be deemed to have occurred if any of the following events shall occur: 

          	(a) 	  	
               The sale, exchange, lease or other disposition, in one or a series of related
               transactions, of all or substantially all of the assets of the Company to a
               “person” or “group” (as such terms are defined or described
               in Sections 3(a)(9), 13(d)(3) or 14(d)(2) of the Exchange Act); 

               

          	(b) 	  	
               Any person or group is or becomes the Beneficial Owner, directly or indirectly,
               of more than 50% of the total Voting Power of the voting stock of the Company
               (or any successor to all or substantially all of the assets of the Company or
               any entity which controls the Company), including by way of merger,
               consolidation or otherwise; 

               

          	(c) 	  	
               Either a merger or consolidation of the Company with or into another person (as
               defined by Section 13(d) or 14(d) of the Exchange Act) if the shareholders of
               the Common Stock of the Company immediately prior to such transaction are not
               the Beneficial Owners of a majority of the outstanding common stock of the
               surviving company or its parent immediately after the transaction; 

               

          	(d) 	  	
               During any period of two (2) consecutive years, individuals who at the beginning
               of such period constituted the Board (together with any new Directors whose
               election by such Board or whose nomination for election by the shareholders of
               the Company was approved by a vote of a majority of the Directors of the Company
               then still in office, who were either Directors at the beginning of such period
               or whose election or nomination for election was previously so approved) cease
               for any reason to constitute a majority of the Board then in office; or 

               

          	(e) 	  	
               A dissolution or liquidation of the Company. 

               

        Notwithstanding
the foregoing, a Change of Control shall not be deemed to have occurred merely as a result
of an underwritten offering of the equity securities of the Company where no Person
(including any “group” (within the meaning of Rule 13d-5(b) under the Exchange
Act)) acquires more than twenty-five percent (25%) of the beneficial ownership interests
in such securities. 

1.9                   "Code"
means the Internal Revenue Code of 1986, as amended. 

1.10                  "Company"
means Nu Skin Enterprises, Inc., a Delaware corporation, or any successor company. 

1.11           “Compensation
Committee” means a committee comprised of the persons who, prior to or at the
time of a Potential Change of Control or an actual Change of Control, are serving as the
members of the Compensation Committee of the Company’s Board. Following the
occurrence of a Potential Change of Control or Change of Control, the Company shall not
have the right to change the individuals who serve on the committee acting as the
Compensation Committee. Any vacancies on such Committee following the occurrence of a
Change of Control shall be filled, if at all, by a vote of at least 75% of the individuals
then still serving as members of the Compensation Committee. 

1.12           “Date of
Termination” means the date of receipt of a Notice of Termination or, if later,
the date of termination of Participant’s employment specified therein. 

1.13                  "ERISA" means the
Employee Retirement Income Security Act of 1974, as amended. 

1.14                  "Exchange Act" means the
Securities Exchange Act of 1934, as amended. 

1.15                    "Excise Tax" has the
meaning set forth in Section 3.1. 

1.16                  "Excise Tax Gross-Up
Payment" has the meaning set forth in Section 3.3(b). 

1.17                  "End Date" means the
18-month anniversary of the Date of Termination. 

1.18           “Good
Reason” means the occurrence of any of the following, without the express written
consent of Participant, after the occurrence of a Change of Control: 

          	(a) 	  	
               the assignment to Participant of any duties inconsistent in any material adverse
               respect with Participant’s position, authority or responsibilities as in
               effect immediately prior to a Change of Control, or any other material adverse
               change in such position, including authority or responsibilities; 

               

          	(b) 	  	
               any failure by the Company to continue to provide Participant with Base Pay,
               incentive compensation opportunities, and other material benefits (including,
               but not limited to, savings plans, defined benefit plans, welfare benefit plans
               and perquisites) at a level which is, in the aggregate, at least equal to that
               in effect immediately prior to a Change of Control, but shall not include any
               reduction in incentive compensation opportunities or other material benefits
               that are part of an across-the-board reduction of the incentive compensation or
               other material benefits of employees who are similarly situated with respect to
               Participant; 

               

          	(c) 	  	
               the Company’s requiring Participant to be based at any office or location
               more than 49 miles from that location at which he performed his services
               immediately prior to the Change of Control, except for travel reasonably
               required in the performance of Participant’s responsibilities; or 

               

          	(d) 	  	
               any failure by the Company or an Affiliate to obtain the commitment of any
               successor in interest or failure on the part of such successor in interest to
               perform the obligations to Participant under this Plan or any employee-related
               obligations assumed by the successor in interest in connection with its
               acquisition of the Company or an Affiliate. 

               

        The
occurrence of the events or conditions in clauses (a)-(d) shall not constitute Good Reason
unless Participant provides written notice of the action(s) or omission(s) deemed to
constitute Good Reason in accordance with the provisions hereof and the Company or, if
applicable, an Affiliate fails to remedy such action(s) or omission(s) within 30 days
after the receipt of such written notice. In no event shall the mere occurrence of a
Change of Control, absent any further impact on Participant, be deemed to constitute Good
Reason. 

1.19                  "Group Welfare Benefit
Plans" has the meaning set forth in Section 2.3(b).  

1.20           “Notice of
Termination” Any termination by the Company (and/or, where applicable, an
Affiliate), whether with or without Cause, or by Participant for Good Reason shall be
communicated by Notice of Termination to Participant or the Company (or the applicable
Affiliate), as the case may be (except that such notice may be waived by the party
intended to receive such notice). A “Notice of Termination” means a written
notice given, in the case of a termination for Cause, within thirty (30) business days of
the Company’s (or the applicable Affiliate’s) having actual knowledge of the
events giving rise to such termination, and in the case of a termination for Good Reason,
within thirty (30) days of Participant’s having actual knowledge of the events giving
rise to such termination, and which (i) sets forth in reasonable detail the facts and
circumstances claimed to provide a basis for termination of Participant’s employment,
and (ii) if the termination date is other than the date of receipt of such notice,
specifies the Date of Termination (which date, in the case of any termination for other
than Good Reason, shall be not more than 15 days after the giving of such notice).
Notwithstanding any other provision hereunder, in the case of a termination for Good
Reason, the Date of Termination shall be 30 days after the Notice of Termination, provided
that Participant may not terminate his or her employment for Good Reason if the Company
(or the applicable Affiliate) cures the cause for such termination within 30 days of
receiving the Notice of Termination. The failure by Participant to set forth in the Notice
of Termination any fact or circumstance which contributes to a showing of Good Reason
shall not waive any right of Participant hereunder or preclude Participant from asserting
such fact or circumstance in enforcing his rights hereunder. A Notice of Termination shall
be given in writing and delivered by first class mail, return receipt requested (or other
form of delivery which requires signature for delivery), addressed to the Company’s
headquarters, if the notice is to the Company (or the applicable Affiliate), or to the
address of Participant on the Company’s (or the applicable Affiliate’s) records,
if addressed to Participant. 

1.21           “Nu Skin
Enterprises Deferred Compensation Plans” means the Nu Skin Enterprises, Inc.
Deferred Compensation Plan and any other deferred compensation plan sponsored by the
Company or any Affiliate that is unfunded and is maintained primarily for the purpose of
providing deferred compensation for a select group of management or highly compensated
employees. 

1.22        
“Participant” means ___________________. 

1.23                  "Payment Cap" has the
meaning set forth in Section 3.3(a). 

1.24           “Person”
means any person (within the meaning of Section 3(a)(9) of the Exchange Act, including any
group (within the meaning of Rule 13d-5(b) under the Exchange Act)), but excluding any of
the Company, any Affiliate or any employee benefit plan sponsored or maintained by the
Company or any Affiliate. 

1.25           “Potential Change
of Control” shall be deemed to have occurred if any of the following events shall
have occurred: 

          	(a) 	  	
               a Person commences a tender offer (with adequate financing) for securities
               representing at least 10% of the Voting Power of the Company’s securities; 

               

          	(b) 	  	
               the Company enters into an agreement the consummation of which would constitute
               a Change of Control; 

               

          	(c) 	  	
               at a time at which the Company is subject to the proxy disclosure rules of
               Section 14 of the Exchange Act, proxies for the election of directors of the
               Company are solicited by anyone other than the Company; or 

               

          	(d) 	  	
               any other event occurs which is deemed to be a Potential Change of Control by
               the Board. 

               

1.26                  "Plan" means the Nu Skin
Enterprises, Inc. Change of Control Severance Plan for ___________________. 

1.27                  "Section 280G
PlaceNameplaceSafe PlaceTypeHarbor Amount" has the meaning set forth in Section 3.2. 

1.28           “Separation
Agreement and General Release” means a written document that includes, but is not
limited to, a release of rights and claims from Participant, a confidentiality agreement,
a non-compete agreement, and an agreement not to solicit employees of the Company and its
Affiliates, in a form substantially similar to Exhibit A, as the same may be amended by
the Compensation Committee from time to time. 

1.29                  "Severance Amount" has
the meaning set forth in Section 2.3(a)(iv). 

1.30           “Voting
Power” means such number of the Voting Securities as shall enable the holders
thereof to cast such percentage of all the votes which could be cast in an annual election
of directors. 

1.31           “Voting
Securities” means all securities of a company entitling the holders thereof to
vote in an annual election of directors. 

1.32           “Year of
Termination” means the calendar year during which Participant’s employment
with the Company or any Affiliate is terminated. 

ARTICLE II  
BENEFITS PAYABLE 

2.1           Death; Disability or
Retirement. If Participant’s employment with the Company and/or any Affiliate is
terminated by reason of Participant’s death, voluntary retirement or termination of
employment as a result of Participant’s inability to perform the basic requirements
of his or her position due to physical or mental limitations, no benefits will be payable
under this Plan. 

2.2           Cause and Voluntary
Termination. If Participant’s employment with the Company and/or any Affiliate is
terminated for Cause or is voluntarily terminated by Participant (other than on account of
Good Reason), no benefits will be payable under this Plan. 

2.3           Termination by the
Company other than for Cause. If, during the two-year period following a Change of
Control, Participant’s employment is terminated by the Company and/or any Affiliate
other than for Cause, the Company shall provide (or the Company shall cause an Affiliate
to provide) Participant with the following compensation and benefits: 

               	(a) 	  	
                    Severance and Other Termination Payments. Participant shall be entitled
                    to receive the following upon the execution of a Separation Agreement and
                    General Release: 

                    

               	(i) 	  	
                    Participant’s full Base Pay through the Date of Termination; 

                    

               	(ii) 	  	
                    an amount (the “Pro-Rated Annual Incentive”) equal to the target
                    annual incentive compensation opportunity applicable to Participant for the
                    fiscal year in which the Date of Termination occurs (or, if there is no target
                    opportunity stated for such year, an amount equal to the average of the annual
                    incentive compensation payments made to Participant for the three calendar years
                    (or, if less, the number of calendar years during which Participant was employed
                    by the Company or any Affiliate) ended immediately prior to Participant’s
                    Year of Termination), multiplied by a fraction, the numerator of which is the
                    number of completed months in such fiscal year which have elapsed on or before
                    (and including) the Date of Termination and the denominator of which is 12; 

                    

               	(iii) 	  	
                    any vested amounts or benefits owing to Participant under any otherwise
                    applicable employee benefit plans and programs, both qualified and nonqualified,
                    and not yet paid and any accrued vacation pay not yet paid by the Company (the
                    “Accrued Obligations”); and 

                    

               	(iv) 	  	
                    a severance payment (the “Severance Amount”) equal to 1.5 times
                    Participant’s Annual Compensation. 

                    

        The
Base Pay, Pro-Rated Annual Incentives, and Severance Amount shall be paid in cash in a
single lump sum as soon as practicable, but in no event more than 30 days (or at such
earlier date required by law) following the later of (a) the Date of Termination or (b)
the execution of a Separation Agreement and General Release. The Pro-Rated Annual
Incentive shall be paid in cash as soon as practicable after the amount of each such
payment (or any portion thereof) can be determined. Accrued Obligations shall be paid in
accordance with the terms of the applicable plan, program or arrangement. 

          	(b) 	  	
               Continuation of Benefits. After the Date of Termination, Participant
               (and, to the extent applicable, his or her dependents) shall be entitled to
               continue participation in all of the group health and group life employee
               benefit plans of the Company or any Affiliate in which he or she participated
               (the “Group Welfare Benefit Plans”) during Participant’s (or if
               applicable, his or her dependents’) applicable coverage period under the
               Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, to the
               degree such participation is permitted under the terms of the applicable plan,
               program or policy and in accordance with the requirements of the Code, ERISA or
               otherwise applicable law. The Company or the appropriate Affiliate shall pay
               Participant, as soon as reasonably practical, a lump-sum payment equal to the
               excess of the cost of the medical coverage and life insurance provided to
               Participant (and to the extent applicable, Participant’s dependents)
               hereunder over the cost that Participant (or his dependents) would have paid for
               such coverage if Participant had remained employed. 

               

        Notwithstanding
the above, to the extent Section 409A of the Code applies to any payment amount under this
Section, payment to Participant will begin no earlier than six months following
Participant’s termination to the extent required by Section 409A of the Code. 

2.4           Termination by
Participant for Good Reason. If, after a Change of Control and prior to the second
anniversary of such Change of Control, Participant terminates his employment for Good
Reason, the Company or the appropriate Affiliate shall provide to Participant the same
amounts and benefits as would be payable to Participant if such termination were a
termination by the Company or such Affiliate without Cause. 

2.5           Termination of
Employment by the Company Following a Potential Change of Control. If the Company or
Affiliate terminates Participant’s employment other than for Cause after the
occurrence of a Potential Change of Control, and within six months after such Potential
Change of Control a Change of Control actually occurs, Participant shall be treated,
solely for purposes of this Plan, to have continued in employment until the occurrence of
the Change of Control and to have been terminated thereafter by the Company and such
Affiliate, without Cause, in which case he or she shall be entitled to the benefits
described in Section 2.3 above, reduced by the amount of any other severance benefits
previously provided to him in connection with such termination (other than any such
benefits payable pursuant to the terms of a plan which is intended to meet the
requirements of Section 401(a) of the Code). 

2.6           Discharge of the
Company’s Obligations. Except as expressly provided herein, the amounts payable
to Participant pursuant to this Plan (whether or not reduced as provided below) shall be
conditioned upon Participant’s executing a Separation Agreement and General Release
in favor of the Company and each Affiliate and certain other parties designated therein of
any claims Participant may have in respect of his employment by any of the Company or any
Affiliate. Any payment under this Plan shall be null and void upon Participant’s
failure to sign, or subsequent revocation of, such Separation Agreement and General
Release. Any breach by Participant of a Separation Agreement and General Release upon
which any payment under this Plan has been conditioned shall give the Company the right to
terminate any payment otherwise due and/or to the return of such amounts already paid
under this Plan, in addition to any other remedy the Company may have. Notwithstanding the
foregoing, nothing in this Plan shall be construed to: 

          	(a) 	  	
               affect, limit or modify in any way or release any claim Participant may have
               with respect to any amounts payable pursuant to this Plan or any vested amounts
               or benefits owing to Participant under any otherwise applicable employee benefit
               plans and programs maintained or contributed by any of the Company or any
               Affiliate (except that this Plan will supersede any otherwise applicable
               severance policy), including any compensation previously deferred by Participant
               (together with any accrued earnings thereon) and not yet paid and any accrued
               vacation pay not yet paid, or 

               

          	(b) 	  	
               release the Company or any Affiliate from its commitment to indemnify
               Participant and hold Participant harmless from and against any claim, loss or
               cause of action arising from or out of Participant’s performance as an
               officer, director or employee of the Company or any such Affiliate or in any
               other capacity, including any fiduciary capacity, in which Participant served at
               the request of the Company or any Affiliate. 

               

        Except
as otherwise expressly provided herein, the obligation of the Company or any Affiliate to
make the payments provided for in this Plan shall not be affected by any circumstances,
including, without limitation, any set-off, counterclaim, recoupment, defense or other
right which the Company or any such Affiliate may have against Participant or others
whether by reason of the subsequent employment of Participant or otherwise. 

ARTICLE III
LIMIT ON PAYMENTS BY
THE COMPANY 

3.1           Application of this
Article III. In the event that any amount or benefit paid or distributed to
Participant pursuant to this Plan, taken together with any amounts or benefits otherwise
paid or distributed to Participant by the Company or any Affiliate (the “Covered
Payments”), would be an “excess parachute payment” as defined in Section
280G of the Code and would thereby subject Participant to the tax (the “Excise
Tax”) imposed under Section 4999 of the Code (or any similar tax that may hereafter
be imposed), the provisions of this Article III shall apply to determine the amounts
payable to Participant pursuant to this Plan. 

3.2 Calculation of
Aggregate Parachute Payments. Immediately following delivery of any Notice of
Termination, the Company shall notify Participant of the aggregate present value of all
“parachute payments” (within the meaning of Section 280G of the Code) to which
Participant would be entitled under this Plan and any other plan, program or arrangement
as of the projected Date of Termination (the “Aggregate Parachute Payments”).
  

3.3                     Best  Alternative
 Payment.  The Aggregate  Parachute  Payments shall be reduced if such reduction  would
maximize the  Participant's  after-tax retention.  For this purpose, the Company shall
perform two calculations, as follows: 

          	(a) 	  	
               the first being the amount the Participant would retain net after all taxes,
               including excise taxes, if all of the Participant’s Aggregate Parachute
               Payments are made; and 

               

          	(b) 	  	
               the second being the amount the Participant would retain net after all taxes if
               the Aggregate Parachute Payments are reduced until no portion of the Aggregate
               Parachute Payments is not deducible by reason of Section 280G of the Code. 

               

        The
Participant will receive the greater of (a) or (b) above, whichever maximizes the
Participant’s net after tax retention. 

3.4           Application of Section
280G. For purposes of determining whether any of the Covered Payments will be subject
to the Excise Tax and the amount of such Excise Tax: 

          	(a) 	  	
               such Covered Payments will be treated as “parachute payments” within
               the meaning of Section 280G of the Code, and all “parachute payments”
               in excess of the “base amount” (as defined under Section 280G(b)(3) of
               the Code) shall be treated as subject to the Excise Tax, unless, and except to
               the extent that, in the good faith judgment of an independent certified public
               accountant other than the Company’s normal independent certified public
               accountants or tax counsel selected by such accountants (the
               “Accountants”), relying on the best authority available at the time of
               such determination (including, but not limited to, any proposed Treasury
               regulations upon which taxpayers may rely), that the Company or any otherwise
               applicable Affiliate has a reasonable basis to conclude that such Covered
               Payments (in whole or in part) either do not constitute “parachute
               payments” or represent reasonable compensation for personal services
               actually rendered (within the meaning of Section 280G(b)(4)(B) of the Code) in
               excess of the “base amount,” or such “parachute payments”
               are otherwise not subject to such Excise Tax, and 

               

          	(b) 	  	
               the value of any non-cash benefits or any deferred payment or benefit shall be
               determined by the Accountants in accordance with the principles of Section 280G
               of the Code. 

               

3.5           Adjustments in
Respect of the Payment Cap. 

          	(a) 	  	
               If Participant receives reduced payments and benefits under this Article III (or
               this Article III is determined not to be applicable to Participant because the
               Accountants conclude that Participant is not subject to any Excise Tax) and it
               is established pursuant to a final determination of a court or an Internal
               Revenue Service proceeding (a “Final Determination”) that,
               notwithstanding the good faith of the parties in applying the terms of this
               Plan, the aggregate “parachute payments” within the meaning of Section
               280G of the Code paid to Participant or for his benefit are in an amount that
               would result in Participant being subject an Excise Tax and Participant would
               still be subject to the payment cap under the provisions of Section 3.3(b), then
               the amount equal to such excess parachute payments shall be deemed for all
               purposes to be a loan to Participant made on the date of receipt of such excess
               payments, which Participant shall have an obligation to repay to the entity
               making such payment on demand, together with interest on such amount at the
               applicable Federal rate (as defined in Section 1274(d) of the Code) from the
               date of the payment hereunder to the date of repayment by Participant. 

               

          	(b) 	  	
               If Participant receives reduced payments and benefits by reason of this Article
               III and it is established pursuant to a Final Determination that Participant
               could have received a greater amount without exceeding the payment cap under the
               provisions of Section 3.3(b), then the Company or the appropriate Affiliate
               shall promptly thereafter pay Participant the aggregate additional amount which
               could have been paid without exceeding the cap, together with interest on such
               amount at the applicable Federal rate (as defined in Section 1274(d) of the
               Code) from the original payment due date to the date of actual payment. 

               

ARTICLE IV  
DISPUTES 

        Any
dispute or controversy arising under or in connection with this Plan shall be resolved by
binding arbitration. The arbitration shall be held in the State of Utah (or such other
location as the parties shall mutually agree to in writing) and shall be conducted in
accordance with the Expedited Employment Arbitration Rules of the American Arbitration
Association then in effect at the time of the arbitration (or such other rules as the
parties may agree to in writing), and otherwise in accordance with principles which would
be applied by a court of law or equity. The arbitrator shall be acceptable to both the
Company and Participant. If the parties cannot agree on an acceptable arbitrator, the
dispute shall be heard by a panel of three arbitrators, one appointed by each of the
parties and the third appointed by the other two arbitrators. If Participant asserts any
claim as to his or her eligibility for benefits under this Plan, Participant’s
employer shall pay Participant’s legal expenses (or cause such expenses to be paid)
including, without limitation, his or her reasonable attorney’s fees, on a quarterly
basis, upon presentation of proof of such expenses in a form acceptable to the Company,
provided that Participant shall reimburse such amounts, plus simple interest thereon at
the 90-day United States Treasury Bill rate as in effect from time to time, compounded
annually, if Participant does not prevail as to at least one material issue presented to
the arbitrator(s). 

ARTICLE V  
GENERAL INFORMATION 

5.1           Administration. The
Plan is sponsored solely by the Company, and will be payable from the general assets of
the Company and, as applicable, an Affiliate. The Plan will be administered by the
Compensation Committee. The Compensation Committee shall have full and complete authority
to interpret this Plan, and to make all determinations hereunder, but not limited to,
making determinations as to eligibility for benefits or to participate in the Plan, the
amount of benefits payable, the time at which benefits cease to be payable, and other
comparable issues. In addition, the Compensation Committee may delegate any of its
authority and responsibilities, subject to Compensation Committee review and to the extent
permitted by law, to any officer or committee of officer(s) of the Company. The
determinations made by the Compensation Committee or its delegate shall be final, binding
and conclusive on all persons affected thereby, including, but not limited to,
Participant, the Company and each Affiliate. The Company and/or the Compensation
Committee, as the case may be, shall maintain such procedures and records as each deems
necessary or appropriate. Participant shall receive a copy of the Plan. 

5.2           Plan Amendment Or
Termination. This Plan may be amended or terminated at any time by the Board, subject
to the following limitations. Any amendment or termination that adversely affects
Participant shall not be given any effect until the expiration of one year from the date
that Participant is given written notice of such amendment or termination. Upon a Change
of Control or any Potential Change of Control, the Plan may not be terminated or amended
in a manner that adversely affects Participant. In the event a Change of Control occurs
during the one-year notice period required with respect to a termination or amendment that
adversely affects Participant, such termination or amendment shall be rendered void and
without effect. The Compensation Committee may terminate Participant’s participation
in the Plan at any time, provided that (i) such termination shall not be given effect
until the expiration of six months from the date that Participant is given notice thereof,
and (ii) Participant’s participation hereunder may not be terminated after a Change
of Control or a Potential Change of Control (even if notice of termination had been given
prior to the occurrence of any such event). Notwithstanding anything else contained herein
to the contrary, no Participant shall be or become entitled to benefits hereunder upon the
termination of his or her employment by the Company, or as a result of any event that
would otherwise have constituted Good Reason hereunder, if such termination or event first
occurs after the second anniversary of the Change of Control occurring during the term of
this Plan. This Plan shall automatically terminate at the later of two years after a
Change of Control or the satisfaction of all Plan liabilities to Participant. 

5.3           No Contract Of
Employment. The existence of this Plan, as in effect at any time or from time to time,
shall not be deemed to constitute a contract of employment between the Company or any
Affiliate and Participant, nor shall it constitute a right to remain in the employ of the
Company or any Affiliate. Employment with the Company or any Affiliate is
employment-at-will and either party may terminate Participant’s employment at any
time, for any reason, with or without cause or notice. 

5.4           Limitation On
Liability. The liability of the Company or any Affiliate under this Plan is limited to
the obligations expressly set forth in the Plan, and no term or provision of this Plan may
be construed to impose any further or additional duties, obligations, or costs on the
Company, any Affiliate or the Compensation Committee not expressly set forth in the Plan. 

5.5           Exclusivity Of
Benefits. Except as otherwise expressly provided herein with respect to a termination
occurring prior to a Change of Control but after a Potential Change of Control,
Participant who receives benefits under this Plan shall not be entitled to any severance
benefits under any other severance plan, program, or arrangement sponsored or adopted by
the Company. 

5.6           Impact on Other
Benefits. Amounts paid under the Plan shall not be included in Participant’s
compensation for purposes of calculating benefits under any other plan, program or
arrangement sponsored by the Company or a Participating Company, unless such plan, program
or arrangement expressly provides that amounts paid under the Plan shall be included. 

5.7           Taxes. The Company
or the appropriate Affiliate shall have the right to deduct from all payments any federal,
state, or local taxes or other obligations required by law to be withheld with respect to
such payments. 

5.8                   Third Parties.  Nothing
 express or implied in this Plan is intended or may be construed to give any person other
than eligible  Participant any rights or remedies under this Plan.  

5.9                   Captions.  The headings
and captions  appearing herein are inserted only as a matter of convenience.  They do not
define,  limit,  construe,  or describe the scope or intent of the provisions of the Plan. 

5.10           Choice Of Law.
Except to the extent that they may be preempted by the operation of Federal law, this Plan
shall be governed by the laws of the State of StateplaceUtah, other than the provisions
thereof relating to conflict of laws. 

5.11           No Limitations On
Corporate Actions. Except to the extent expressly provided in Section 5.2, nothing
contained in this Plan shall be construed to prevent the Company, or any Affiliate, from
taking any corporate action which is deemed by it to be appropriate, or in its best
interest, whether or not such action would have an adverse effect on this Plan. No
employee, beneficiary, or other person, shall have any claim against the Company or any
Affiliate as a result of any such action. 

5.12           Non-Alienation
Provision. Subject to the provisions of applicable law, no interest of any person or
entity in any benefit under the Plan shall be subject in any manner to sale, transfer,
assignment, pledge, attachment, garnishment, or other alienation or encumbrance of any
kind; nor may such benefit be taken, either voluntarily or involuntarily, for the
satisfaction of the debts of, or other obligations or claims against, such person or
entity, including (but not limited to) claims for alimony, support, separate maintenance
and claims in bankruptcy proceedings.   

5.13           Successors. All
obligations of the Company and any Affiliate under the Plan shall be binding upon and
inure to the benefit of any successor to the Company or such Affiliate, whether the
existence of such successor is the result of a direct or indirect purchase, merger,
consolidation, demutualization or otherwise. 

        To
signify its adoption of this Plan document, the Company has caused this Plan document to
be executed by a duly authorized officer of the Company on this August 9, 2006. 

	  	  	NU SKIN
ENTERPRISES, INC.  
	  	  	   
	  	  	   
	  	By:	      
	  	  	   
	  	Its:exv10w39

 

Exhibit 10.39

			
	[..**..] = Certain Confidential Information Contained

in this Document, Marked by Brackets, Has Been

Omitted and Filed Separately with the Securities

and Exchange Commission Pursuant to rule 24b-2

of the Securities Exchange Act of 1934, as Amended.

AMENDED AND RESTATED

COLLABORATION AND OPTION AGREEMENT

by and between

Myogen, Inc.

and

Novartis Institutes for BioMedical Research, Inc.

[..**..] Confidential Treatment Requested

 

 

AMENDED AND RESTATED

COLLABORATION AND OPTION AGREEMENT

     This Amended and Restated Collaboration and Option Agreement (this “Agreement”)
is made this 7th day of July, 2006 (the “Restatement Date”) by and between
Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 W.
103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical
Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology
Square, Cambridge, Massachusetts 02139.

Introduction

     WHEREAS, Myogen and NIBRI are parties to that certain Collaboration and Option Agreement
(the “Original Agreement”) dated October 8, 2003 (the “Effective Date”) pursuant
to which the parties have agreed to collaborate on projects to identify and validate compounds
which act on Myogen Targets (as defined below), and thereafter for NIBRI and its Affiliates to have
the option to develop, market and sell certain of those compounds as drugs upon the terms set forth
in the Original Agreement and in the form of License Agreement (as defined therein);

     WHEREAS, the parties amended the Original Agreement pursuant to that certain Amendment to
Collaboration and Option Agreement (the “Amendment” and together with the Original
Agreement, the “Amended Agreement”) dated May 23, 2005 (the “Amendment Date”)
pursuant to which the parties have agreed to add Myogen’s intellectual property on histone
deacetylase protein (“HDAC”) inhibitors for heart muscle disease to the existing
collaboration and to accommodate conducting a collaborative project relating to the use of HDAC
inhibitors in the treatment of heart muscle disease; and

     WHEREAS, NIBRI wishes to exercise its unilateral option to extend the collaboration for an
additional two (2) year period and the parties wish to further amend and restate the Amended
Agreement, effective as of the Effective Date, and accept the rights and covenants herein in lieu
of their rights and covenants under the Amended Agreement to provide for, among other things,
certain clarifications regarding the limitation of certain payments and rights to the Field (as
defined herein);

[..**..] Confidential Treatment Requested

 

 

     NOW THEREFORE, in consideration of the mutual covenants set forth in this Agreement, and other
good and valuable consideration, the parties agree as follows:

ARTICLE I

Definitions

     1.1. “Active Compound” shall mean any chemical compound that has (i) a specific, desired
therapeutic action on, (ii) a specific, desired interaction on, or (iii) a specific, desired
modulation of a Myogen Target or a Collaboration Target, and any and all compounds having the same
Active Moiety as such Active Compound, whether a small molecule, protein or antibody.

     1.2. “Active Moiety” shall have the meaning assigned to that term under 21 CFR 314.108(a), as
such regulation is in effect on the Effective Date; namely: “the molecule or ion excluding those
appended portions of the molecule that cause the drug to be an ester, salt (including a salt with
hydrogen or coordination bonds), or other noncovalent derivative (such as a complex, a chelate or
clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug
substance.”

     1.3. “Affiliate” shall mean, with respect to any Person, any other Person that, directly or
indirectly, by itself or through one or more intermediaries, controls, or is controlled by, or is
under common control with, such Person. The term “control” means the possession, direct or
indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise. Control will be
presumed if one Person owns, either of record or beneficially, at least 50% of the voting stock of
any other Person. Such other relationship as in fact results in actual control over the
management, business, and affairs of a Person shall also be deemed to constitute control;
provided, however, that no Person shall be deemed to exercise control over another
Person solely because the latter relies on the former for a majority of its business. A Person
will be deemed an Affiliate only so long as such ownership or control relationship continues. In
the case of NIBRI, “Affiliates” shall also expressly be deemed to include the Novartis Institute
for Functional

[..**..] Confidential Treatment Requested

2

 

Genomics, Inc., and the Friedrich Miescher Institute for BioMedical Research and their
respective Affiliates.

     1.4. “Collaboration Compound” shall mean any chemical compound utilized by either party in the
course of the Research Program, including Collaboration HDAC Inhibitor Compounds, but explicitly
excluding all NIBRI Compounds, NIBRI HDAC Inhibitor Compounds and Myogen Compounds.

     1.5. “Collaboration HDAC Inhibitor Compound” shall mean any HDAC Inhibitor Compound other than
a NIBRI HDAC Inhibitor Compound or a Myogen Compound which is an HDAC Inhibitor Compound,
including, without limitation, all derivatives and analogs of Collaboration HDAC Inhibitor
Compounds and all derivatives and analogs of NIBRI HDAC Inhibitor Compounds that do not fall within
the definition of NIBRI HDAC Inhibitor Compounds set forth herein. In no event, however, shall any
In-Licensed NIBRI HDAC Inhibitor Compound be a Collaboration HDAC Inhibitor Compound.

     1.6. “Collaboration Target” shall mean any Target identified for the first time in the course
of the Research Program or a Development Program.

     1.7. “Collaboration Technology” shall mean any Technology that relates to Collaboration
Targets and/or Collaboration Compounds.

     1.8. “Compound” shall mean any Myogen Compound, NIBRI Compound, or Collaboration Compound and
other compounds having the same Active Moiety as a Myogen Compound, NIBRI Compound, or
Collaboration Compound.

     1.9. “Controlled” shall mean, with respect to a Target or Technology, the legal authority or
right of a party hereto to grant a license or sublicense of intellectual property rights to another
party hereto, or to otherwise disclose proprietary or trade secret information to such other party,
without breaching the terms of any agreement with a Third Party, infringing upon the intellectual
property rights of a Third Party, or misappropriating the proprietary or trade secret information
of a Third Party. A party shall be deemed to “Control” a Compound, including determining the
relative rights of the parties to intellectual property under Section 8.1, if (i) that party
contributed or otherwise made available to the collaboration such Compound or

[..**..] Confidential Treatment Requested

3

 

(ii) such Compound is an analog, derivative, enantiomer, racemate, isomer, diastereomer,
active metabolite or pharmaceutically acceptable salt or complex of a Compound contributed by such
party.

     1.10. “Critical Issues” shall have the meaning set forth in Section 2.8.2 hereof.

     1.11. “Development Candidate” shall mean a NIBRI Compound, Myogen Compound or Collaboration
Compound, and derivatives thereof, together with the Myogen Target or Collaboration Target on which
it has therapeutic action, as to which NIBRI exercises its Option pursuant to Section 4.4 of this
Agreement.

     1.12. “Development Program” shall mean activities associated with development of a Development
Candidate as specified in the License Agreement.

     1.13. “Effective Date” shall mean the effective date of the Original Agreement as set forth in
the Introduction hereto.

     1.14. “Field” shall mean the research, treatment, prognosis, diagnosis, prophylaxis, and
monitoring of heart muscle disease.

     1.15. “FTE” shall mean the equivalent of the work of one Myogen scientist or other project
managerial professional, full time for one year, which equates to a total of [..**..]
hours per year of work, on or directly related to the Research Program, including attendance at
relevant scientific seminars and symposia. FTEs shall include equivalent scientific work in the
Research Program delegated to and carried out by contractors (including Myogen’s academic
collaborators) under the general direction of Myogen scientists. The annual rate per FTE shall be
[..**..].

     1.16. “GCP” shall mean the current Good Clinical Practice standards for clinical trials for
pharmaceuticals, as set forth in the Food, Drug and Cosmetic Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good clinical practice
as are required by the regulatory authorities of the organizations and governmental agencies in
countries in which Drug Products (as defined in the License Agreement) are intended to be sold.

[..**..] Confidential Treatment Requested

4

 

     1.17. “GLP” shall mean the current Good Laboratory Practices regulations promulgated by the
Food and Drug Administration, published at 21 CFR Part 58, as such regulations may be from time to
time amended, and such equivalent regulations or standards of countries outside the United States
as may be applicable to activities conducted hereunder.

     1.18. “HDAC” shall mean any histone deacetylase protein.

     1.19. “HDAC Inhibitor Compound” shall mean any Active Compound that has a specific, desired
therapeutic action through its ability to bind directly to an HDAC and inhibit HDAC activity.

     1.20. “HDAC Inhibitor Research Program” shall mean the Research Program undertaken jointly by
the parties as of the Amendment Date associated with the identification, design and development of
HDAC Inhibitor Compounds.

     1.21. “HDAC License Agreement” shall mean the License, Development and Commercialization
Agreement, identical in substance to Exhibit A-2 to this Agreement, to be executed by
Myogen and NIBRI with respect to each Development Candidate that is an HDAC Inhibitor Compound.

     1.22. “IC50” shall mean the concentration of a compound that reduces activity of an
enzyme by 50% in a standard, validated assay.

     1.23. “IND” shall mean an application to the Food and Drug Administration, the filing of which
is necessary to commence clinical testing of Compounds in humans, or the equivalent application to
the equivalent agency in any other country or group of countries.

     1.24. “In Vivo Validation” means, with respect to a Myogen Compound, Collaboration Compound or
NIBRI Compound, the achievement of physiologically significant activity in an appropriate in vivo
model or models, where the level of physiological significance and the in vivo model(s) to be used
will be specified by the JSC with respect to High Priority Targets and Low Priority Targets and by
Myogen with respect to Extra-Collaboration Targets.

     1.25. “Joint Steering Committee” or “JSC” shall have the meaning set forth in Section 2.5
hereof.

[..**..] Confidential Treatment Requested

5

 

     1.26. “Know-How” means all Technology other than inventions that are the subject of Patents.

     1.27. “License Agreement” shall mean a License, Development and Commercialization Agreement,
identical in substance to Exhibit A-1 hereto (with respect to any Development Candidate
that is not an HDAC Inhibitor Compound) or identical in substance to Exhibit A-2 hereto
(with respect to any Development Candidate that is an HDAC Inhibitor Compound), to be executed by
Myogen and NIBRI with respect to a particular Development Candidate.

     1.28. “Myogen Compound” shall mean any compound (i) Controlled by Myogen, its Affiliates,
and/or its external academic collaborators (or, if applicable, by the licensor or assignor to
Myogen or its Affiliates if the rights to such compound were licensed to or acquired by Myogen or
its Affiliates) and all enantiomers, racemate(s), isomers, diastereomers, active metabolites and
pharmaceutically acceptable salt or complex thereof and any Active Moiety, analog or derivative of
such Myogen Compound or the foregoing, and (ii) with respect to which NIBRI’s Head of CV Chemistry
or his designee consented to the contribution of such compound to the collaboration. If such
consent is not given, such compounds shall remain outside of the collaboration. For the avoidance
of doubt, the parties acknowledge that NIBRI or one or more of its employees, agents or Affiliates
previously contented to the contribution of certain dihydrotheino pyridine compounds to the
collaboration and that such compounds and all derivatives and analogs thereof are Myogen Compounds.

     1.29. “Myogen Know-How” shall mean all Know-How of Myogen or its Affiliates relating to a
Myogen Compound, a Collaboration Compound, a Collaboration Target, or a Myogen Target or relating
to or used in connection with the Research Program.

     1.30. “Myogen Patents” shall mean any Patents Controlled by Myogen or any of its Affiliates
relating to the Myogen Targets, Myogen Compounds, Collaboration Targets, Collaboration Compounds,
and methods or reagents used in identifying, using, developing or manufacturing such Myogen
Targets, Myogen Compounds, Collaboration Targets, and Collaboration Compounds, as applicable. A
list of Myogen Patents is appended hereto as

[..**..] Confidential Treatment Requested

6

 

Schedule 1.30 and will be updated periodically to reflect additions thereto during the course
of this Agreement.

     1.31. “Myogen Target” shall mean any Target Controlled by Myogen or identified and/or
synthesized by Myogen, its Affiliates, and/or its external academic collaborators in the Field,
including, as of the Amendment Date, any Targets within the HDAC Inhibitor Research
Program. A list of High Priority Myogen Targets as of the date hereof is set forth on Schedule
1.31 appended hereto. Such Schedule 1.31 may be updated periodically to reflect additions thereto
during the course of this Agreement.

     1.32. “Myogen Technology” shall mean all Myogen Patents and Myogen Know-How.

     1.33. “NIBRI Competitor” means a Person with annual pharmaceutical sales of [..**..]
or more.

     1.34. “NIBRI Compound” shall mean any compound (i) Controlled by NIBRI and/or its Affiliates
and all enantiomers, racemate(s), isomers, diastereomers, active metabolites and pharmaceutically
acceptable salt or complex thereof and any Active Moiety, analog or derivative of such NIBRI
Compound or the foregoing, and (ii) with respect to which Myogen’s Head of Chemistry or his
designee consented to the contribution of such compound to the collaboration. If such consent is
not given, such compounds shall remain outside of the collaboration. For the avoidance of doubt,
the parties acknowledge that Myogen or one or more of its employees, agents or Affiliates
previously consented to the contribution of certain compounds on Schedule 1.34 to the collaboration
and that such compounds and all derivatives and analogs thereof are NIBRI Compounds. For the
avoidance of doubt, an HDAC Inhibitor fulfilling criteria (i) and (ii) above shall be a NIBRI
Compound (regardless of whether such HDAC Inhibitor is a NIBRI HDAC Inhibitor Compound or
Collaboration HDAC Inhibitor Compound as used herein and in a License Agreement for, among other
things, determination of applicable milestone and royalty payment obligations).

     1.35. “NIBRI HDAC Inhibitor Compound” shall mean any of the following:

          (a) Except as otherwise provided in Section 3.6 of the License Agreement relating to any
Active Compound that is deemed to be a Development Candidate, a HDAC

[..**..] Confidential Treatment Requested

7

 

Inhibitor Compound first synthesized by NIBRI or its Affiliates outside of the collaboration
contemplated by this Agreement and for which NIBRI or its Affiliates have received or have applied
for or could reasonably expect to apply for and receive U.S. composition of matter patent coverage
and that: (i) is shown to have an IC50 of less than or equal to 1 μM (micromolar) in
any standard NIBRI in vitro assay for the inhibition of HDAC activity; and (ii) has been designated
a “Lead Series” candidate for follow-up under the designation “Research Phase D3” in accordance
with the standard drug development terminology used by NIBRI; and

          (b) Except as otherwise provided in Section 3.6 of the License Agreement relating to any
Active Compound that is deemed to be a Development Candidate, a HDAC Inhibitor Compound licensed
to, purchased or otherwise acquired by NIBRI or its Affiliates from a third party for which (i)
NIBRI or its Affiliates do not have any material future license, royalty or similar payment
obligations (as determined in good faith by the JSC), and (ii) the third party licensor or assignor
or NIBRI or its Affiliates have received or have applied for or could reasonably expect to apply
for and receive U.S. composition of matter patent coverage and that (i) is shown to have an
IC50 of less than or equal to 1 μM (micromolar) in any standard NIBRI in vitro assay for
the inhibition of HDAC activity; and (ii) has been designated a “Lead Series” candidate for
follow-up under the designation “Research Phase D3” in accordance with the standard drug
development terminology used by NIBRI; and

          (c) Except as otherwise provided in Section 3.6 of the License Agreement relating to any
Active Compound that is deemed to be a Development Candidate, all derivatives and analogs of the
compounds described in subsections (a) and (b) above that are shown to have an IC50 of
less than or equal to 100 nM (nanomolar) as determined by at least one standard in vitro assay for
the inhibition of HDAC activity; and

          (d) A HDAC Inhibitor Compound licensed to, purchased or otherwise acquired by NIBRI or its
Affiliates from a third party for which NIBRI or its Affiliates have any material future license,
royalty or similar payment obligation (as determined in good faith by the JSC) and all derivatives
and analogs of the compounds described in this subsection (d) for which NIBRI or its Affiliates
have any material future license, royalty or similar payment obligation (as

[..**..] Confidential Treatment Requested

8

 

determined in good faith by the JSC) (collectively, “In-Licensed NIBRI HDAC Inhibitor
Compounds”).

     1.36. “NIBRI Know-How” shall mean all Know-How of NIBRI or its Affiliates relating to a NIBRI
Compound, a Collaboration Compound, a Collaboration Target, or a Myogen Target.

     1.37. “NIBRI Patents” shall mean any Patents Controlled by NIBRI or any of its Affiliates
relating to NIBRI Compounds, Collaboration Compounds, Myogen Targets, Collaboration Targets, and
methods or reagents used in identifying, developing, or manufacturing such NIBRI Compounds,
Collaboration Targets, and Collaboration Compounds, as applicable, as in effect on the Effective
Date and at any time during the term of this Agreement.

     1.38. “NIBRI Technology” shall mean all NIBRI Patents and NIBRI Know-How.

     1.39. “Patents” means all existing patents and patent applications and all patent applications
hereafter filed, including any continuation, continuation-in-part, division, provisional or any
substitute applications, any patent issued with respect to any such patent applications, any
reissue, reexamination, renewal or extension (including any supplementary protection certificate)
of any such patent, and any confirmation patent or registration patent or patent of addition based
on any such patent, and all foreign counterparts of any of the foregoing.

     1.40. “Person” means any individual, corporation, partnership, association, joint-stock
company, trust, unincorporated organization or government or political subdivision thereof.

     1.41. “Research Plan” shall have the meaning set forth in Section 2.3.1 hereof.

     1.42. “Research Program” shall mean research activities and development activities undertaken
under this Agreement, associated with the identification, design and development of Targets,
Compounds and Development Candidates as provided herein, including but not limited to:
identification and initial testing of Targets and Compounds; selection of Development Candidates
from Targets and Compounds and preparation for preclinical assessment of those Development
Candidates; formulation and manufacture of Development Candidates for use in

 [..**..] Confidential Treatment Requested

9

 

preclinical and clinical studies performed in accordance with GCP; preclinical animal studies
performed in accordance with GLP (or the applicable equivalent); planning, implementation,
administration and evaluation of human clinical trials performed in accordance with GCP and
included in proof of concept studies; and manufacturing process development and scale-up as
appropriate at the stage of development encompassed within the proof of concept studies.

     1.43. “Research Program Costs” shall mean extraordinary external expenses and capital costs
that are approved in advance by the JSC and incurred by or on behalf of a party in connection with
the conduct of the Research Program.

     1.44. “Research Year” means a twelve (12) month period during the term of a Research Program
commencing on October 1 of a given year, and ending on September 30 of the following year. The
first Research Year hereunder shall be deemed to have commenced on October 1, 2003.

     1.45. “Target” shall mean any biological entity identified as being potentially involved in
one or more disease states.

     1.46. “Technology” shall mean all data, technical information, know-how, experience,
inventions (whether or not patented), trade secrets, processes and methods discovered, developed or
applied (with the consent of its owner) and Controlled by either party or its Affiliates, in
connection with performance by either party under the Research Program, or in connection with the
conduct of a Development Program under a License Agreement, that relate to the research,
development, utilization, manufacture or use of Compounds, Targets, or Development Candidates, as
applicable.

     1.47. “Territory” shall mean worldwide.

     1.48. “Third Party” shall mean any Person that is not a party or an Affiliate of any party to
this Agreement.

     1.49. “Wind-Down Period” shall have the meaning set forth in Section 9.4 hereof.

     1.50. “Work Plan” shall have the meaning set forth in Section 2.3.2 hereof.

 [..**..] Confidential Treatment Requested

10

 

     Capitalized terms used but not otherwise defined herein that are defined in the License
Agreement shall have the meaning ascribed to them therein.

ARTICLE II

Research Program

     2.1. Commencement.

            The Research Program shall commence as soon as practicable after the Effective Date. The
Joint Steering Committee shall direct the conduct of the Research Program and Myogen and NIBRI
shall collaborate in the conduct of the Research Program, with the parties having the roles and
responsibilities specified in the Research Plan and/or applicable Work Plans, all as may be deemed
appropriate by the Joint Steering Committee. The Joint Steering Committee shall review and
coordinate the efforts of the parties with respect to the Research Program.

     2.2. Term.

            The Research Program will conclude five (5) years from the Effective Date, for all Projects
other than the HDAC Inhibitor Research Program, and three (3) years from the Amendment Date for the
HDAC Inhibitor Research Program, unless earlier terminated in accordance with the provisions
hereof. Unless earlier terminated in accordance with the provisions hereof, the Research Program
may be extended for additional one (1) year periods upon the mutual written agreement of Myogen and
NIBRI prior to the end of the then current Research Year.

 [..**..] Confidential Treatment Requested

11

 

     2.3. Research Plan; Work Plans.

          2.3.1. Research Plan, Generally. NIBRI, in consultation with Myogen, will prepare an
overall research plan (the “Research Plan”) for the Research Program. The initial outline
of the Research Plan was attached to the Original Agreement. A final version of the Research Plan
was submitted to the Joint Steering Committee for approval at the first meeting of the Joint
Steering Committee. The Research Plan will be revised, updated and submitted to the Joint Steering
Committee at least semi-annually for its review and comment.

          2.3.2. Work Plans. Within thirty (30) days of the Effective Date, the parties will
agree upon an initial work plan (a “Work Plan”) identifying: (a) priorities with respect
to programs, Targets, and Compounds (“Projects”) to be pursued; (b) the responsibilities of
each party with respect to the same; (c) the appropriate resources of each party to be committed to
the Projects; and (d) developmental milestones, performance criteria, and timeframes with respect
to such Projects. The Work Plan shall be submitted for approval at the first meeting of the JSC.
It is anticipated that the number of Projects selected for the Work Plan will be no less than three
(3) at any time during the collaboration, unless otherwise agreed to by the parties.

          2.3.3. Plan Review. The Research Plan and all Work Plans will be reviewed as
necessary at each meeting of the Joint Steering Committee, and at any other time upon the request
of either party, and shall be modified as appropriate to reflect material scientific or commercial
developments. Any disagreements between the parties with respect to modification of the Research
Plan or a Work Plan will be resolved in accordance with Section 2.8 of this Agreement.

          2.3.4. Research Diligence. Each of Myogen and NIBRI shall work diligently and shall
use commercially reasonable efforts to fulfill its respective obligations under the Research Plan
and any Work Plan. In connection therewith and subject to the intellectual property ownership
provisions contained in this Agreement, NIBRI shall make available such NIBRI Compounds as may be
reasonably necessary to carry out the purposes hereof and Myogen shall make available such Myogen
Compounds as may be reasonably necessary to carry out the purposes hereof. Each of NIBRI and
Myogen shall further make available all data and information regarding such Compounds that are
reasonably necessary for the parties to carry out

 [..**..] Confidential Treatment Requested

12

 

the purposes of the collaboration and as reasonably required for achievement of collaboration
milestones, including, without limitation, chemical structure, testing data, pharmacokinetic data,
selectivity data, SAR data, toxicological data and potency data (including potency data versus
target, target isoforms and other related targets) relating to such Compounds. In addition, during
the term of this Agreement and pursuant to the Research Plan, NIBRI shall provide medicinal
chemistry and other drug discovery services relating to lead compound characterization such as
determination of physicochemical properties, cytotoxicity measurements, hERG channel activity, and
determination of biopharmaceutical properties as is reasonably necessary for the parties to carry
out the purposes of the collaboration and as reasonably required for achievement of collaboration
milestones. Consistent with the terms of this Agreement, each party shall use commercially
reasonable efforts to obtain intellectual property protection, including U.S. and worldwide patent
protection, for inventions within the Field of this Agreement.

          2.3.5. Submission of Reports. Upon achieving the developmental milestones specified
in a Work Plan with respect to a particular Project, Myogen and NIBRI will complete and present to
the JSC a report containing detailed summaries of the data for the Project specified in the Work
Plan.

     2.4. Addition of HDAC Inhibitor Research Program.

          Within thirty (30) days of the Amendment Date the parties agreed upon a Work Plan that
conforms to the requirements of Section 2.3.1 and specified the pertinent details of the HDAC
Inhibitor Research Program. The Work Plan was approved at the first meeting of the JSC after the
Amendment Date. The parties will make any revisions to the Research Plan necessary to implement
the HDAC Inhibitor Research Program. Furthermore, the parties hereby agree that initially any
Targets within the HDAC Inhibitor Research Program will be deemed to be High Priority Targets
within the meaning of Section 4.3.1.

 [..**..] Confidential Treatment Requested

13

 

     2.5. Joint Steering Committee.

          Upon execution of this Agreement, Myogen and NIBRI established a Joint Steering Committee
(“JSC”), which consists of an equal number of executives or scientists as may be designated
by each party from time to time. The JSC shall have six (6) members or such other number as
mutually agreed by the Parties. If the JSC chooses to designate a Committee Chair, the Chair will
be appointed from among the members of the JSC designated by NIBRI. The JSC shall meet quarterly,
or with such other frequency as may be established by the JSC (but in no event less often than
three (3) times per year), and at such time and location as may be established by the JSC, for the
following purposes:

	 	(a)	 	Provide general oversight of the entire collaboration between
Myogen and NIBRI, including the Research Program and any development and
commercialization of a Development Candidate under a License Agreement;
	 
	 	(b)	 	Periodically review the overall goals and strategy of the
Research Program;
	 
	 	(c)	 	Prioritize the allocation of resources dedicated to the
Research Program;
	 
	 	(d)	 	Resolve any disagreement between the parties with regard to a
particular Development Candidate, and discuss and resolve any other relevant
issues submitted to it, in accordance with the dispute resolution procedure set
forth in Section 2.8 below;
	 
	 	(e)	 	Review, make a preliminary assessment of and, as applicable,
submit milestone completion and payment submissions to the NIBRI committees as
set forth in Section 3.5 within 30 days of submission to the JSC by Myogen or
NIBRI; and
	 
	 	(e)	 	Address any matters raised under relevant provisions of a
License Agreement.

[..**..] Confidential Treatment Requested

14

 

          The JSC shall have the authority to create project teams for the Research Program, each of
which will meet (via telephone or video conference or in person) no less frequently than monthly,
and which will report to the JSC on its progress on activities performed on the Research Program.
The JSC shall also have the authority to create additional subcommittees as needed.
Notwithstanding the foregoing, the JSC shall not have the authority to amend or modify the terms of
this Agreement.

     2.6. Exchange of Information.

          2.6.1. Myogen and NIBRI will share information with the JSC, as soon as it is available,
necessary to facilitate mutual understanding of the status of the Research Program and
decision-making in connection therewith, including all data specified in Section 2.3.4.

          2.6.2. Except as otherwise agreed by the parties, neither Myogen nor NIBRI shall use
Technology disclosed or Controlled by the other party (excluding information which is no longer
subject to confidentiality restrictions under Article V by reason of the exceptions set forth in
Section 5.2(a), (b) and (c)) for any purpose, including the filing of Patent applications
containing such information without the other party’s consent (which shall not be unreasonably
withheld), other than for carrying out the Research Program or discharging its responsibilities
under a License Agreement, or as otherwise permitted under this Agreement or a License Agreement.

          2.6.3. Upon conclusion of the Research Program and subject to the provisions of Section 2.6.2,
Section 2.6.4 and Article V hereof, each party shall disclose to the other all technical
information known to it which constitutes NIBRI Technology or Myogen Technology, as the case may
be.

          2.6.4.

	 	(a)	 	Neither party shall be entitled to information from the other
party concerning know-how or technology discovered or developed by that party
outside the Research Program or outside a Development Program under a License
Agreement (except as otherwise provided in a License Agreement) or otherwise
unrelated to research or development of Targets,

[..**..] Confidential Treatment Requested

15

 

	 	 	 	Compounds or Development Candidates under this Agreement or a License
Agreement; except that each party must disclose to the JSC in a
timely manner any and all know-how and/or technology which it discovers or
develops regarding: (i) the Myogen Targets; (ii) the Collaboration Targets;
or (iii) any Collaboration Technology.
	 
	 	(b)	 	Neither party will apply its rights in any Technology or the
use thereof (and will use best efforts to prevent its licensees, if any, from
applying similar rights acquired by license) to block or impede the use of such
Technology as permitted hereunder by the other party or its assignees or
licensees.

     2.7. Primary Data Access.

          Myogen and NIBRI shall grant each other access to all data (including, without limitation, all
primary data and data contained in laboratory notebooks) generated in the course of performing its
obligations under the Research Program, including the data referenced in Section 2.3.4. Each party
shall have the right, at reasonable intervals and at such party’s own expense, to make copies of
such data to use and transfer as permitted hereunder.

     2.8 Decisions of the JSC; Resolution of Disputes.

             2.8.1. The JSC shall make decisions unanimously where possible, but at least by majority vote.
In the event of a deadlock, NIBRI shall have the deciding vote on all matters other than those
addressed in Section 2.8.2.

             2.8.2. In the event that the JSC is deadlocked as to: (a) any proposed significant
reorientation of the entire Research Program; or (b) any material change in financial or other
resources required to be expended by Myogen in connection with the Research Program;
(“Critical Issues”) then the parties may have the issue resolved in accordance with the
dispute resolution mechanism set forth in Section 11.3 hereof.

ARTICLE III

Payments

[..**..] Confidential Treatment Requested

16

 

     3.1. Signature Payments by NIBRI.

          The Parties acknowledge that, within thirty (30) days of the Effective Date, NIBRI made an
initial payment of four million dollars ($4,000,000) to Myogen, of which: (a) one million
($1,000,000) was in consideration of licenses hereunder; and (b) three million ($3,000,000) was a
reimbursement of Myogen’s past investment in research and development of the Myogen Technology. In
addition, within thirty (30) days of the Amendment Date, NIBRI made an initial payment of one
million dollars ($1,000,000) to Myogen, of which: (x) two hundred fifty thousand dollars ($250,000)
was in consideration of licenses hereunder; and (y) seven hundred fifty thousand dollars ($750,000)
was a reimbursement of Myogen’s past investment in research and development of the Myogen
Technology.

     3.2. Additional Cash Payment.

          The Parties also acknowledge that NIBRI made an additional payment of one million dollars
($1,000,000) within thirty (30) days after the first anniversary of the Effective Date as a
reimbursement of Myogen’s past investment in research and development of the Myogen Technology.

     3.3. Staffing and Research Support Payments.

          NIBRI will pay to Myogen: (a) [..**..]; and (b) [..**..]. Subject to the
following sentence, the JSC shall determine the exact number of FTEs to be funded by NIBRI in any
particular Research Year and the manner in which such FTEs shall be allocated under the Research
Program. Between [..**..] FTEs shall be funded by NIBRI in any Research Year in
connection with the Research Program, subject to Section 9.4. The JSC shall allocate the FTEs
between the HDAC Inhibitor Research Program and the Research Program excluding the HDAC Inhibitor
Research Program. Any FTEs greater than [..**..] require NIBRI’s prior approval. The
annual rate per FTE shall be [..**..]. The FTEs shall be funded in support of the
Research Program under this Agreement.

          Payments due for each Research Year shall be made by NIBRI to Myogen [..**..] All
payments shall be made without deduction for withholding or other similar taxes, in United States
dollars to the credit of such bank account as may be designated by Myogen in writing to

 [..**..] Confidential Treatment Requested

17

 

NIBRI. Any payments which fall due on a date which is a legal holiday in the Commonwealth of
Massachusetts may be made on the next following day which is not a legal holiday in the
Commonwealth. Any amount that is not paid when due will accrue interest at the rate of
[..**..] per month from the due date until paid.

          In the event that NIBRI terminates its participation in the HDAC Inhibitor Research Program or
the Research Program (excluding the HDAC Inhibitor Research Program) pursuant to Section 9.4, it
shall nevertheless continue the level of funding during the Wind-Down Period set forth in Section
9.4.

     3.4. Records.

          Myogen shall keep accurate records and books of accounts containing all data reasonably
required for the calculation and verification of FTEs employed by, or equivalents supplied by,
Myogen in accordance with the Research Plan.

          At NIBRI’s request, Myogen shall make those records available, no more than once a year,
during reasonable working hours, for review by a recognized independent accounting firm acceptable
to both parties, at NIBRI’s expense, for the sole purpose of verifying the accuracy of those
records in the calculation of Research Program FTEs. NIBRI shall use commercially reasonable
efforts to cause the accounting firm to retain all such information in confidence.

          In the event that (a) the average number of FTEs stated to be involved in the Research Program
is greater than (b) the number of FTEs actually employed, the amount previously advanced to Myogen
and attributable to any such difference shall be due and payable to NIBRI without delay. If the
difference is more than [..**..] in any Research Year, then Myogen shall also pay the
reasonable costs of the independent accountant employed by NIBRI in the review. Interest at the
rate of [..**..] per month, assessed from the end of the Research Year to which the
difference relates, shall be due from Myogen.

     3.5. Milestone Payments.

 [..**..] Confidential Treatment Requested

18

 

          NIBRI shall make milestone payments to Myogen in accordance with this Section 3.5: (a) with
respect to each Myogen Compound, Collaboration Compound or NIBRI Compound having an effect on a
High Priority Target, as defined below (whether or not an Option, as defined below, has been
exercised), within [..**..] of the achievement of such milestone; and (b) with respect to
each Myogen Compound, Collaboration Compound or NIBRI Compound having an effect on a Low Priority
Target (as to which NIBRI has exercised its Option), payment within [..**..] days of
exercise of the Option for all prior milestones achieved. The achievement of a pre-clinical
milestone shall be determined as follows: (i) Myogen shall submit to the JSC documentation
supporting the payment of such milestone; (ii) the JSC shall have [..**..] days in which
to review the submissions and recommend support to the appropriate NIBRI committees; (iii) the
NIBRI committees shall have [..**..] days to review the submission; and (iv) the NIBRI
committees shall, within such [..**..] day period, determine in good faith if such
milestone has been achieved. Any such determination shall be subject to the dispute resolution
provisions set forth in Section 11.2. In the event the NIBRI committees do not make a
determination regarding the achievement of one or more milestones within such [..**..] day
period, the matter may be referred by either party to the President and Chief Executive Officer of
Myogen and the President and Chief Executive Officer of NIBRI who shall, as soon as practicable,
attempt in good faith to resolve the controversy or claim. If such matter is not resolved within
[..**..] days of the date of initial referral of the matter to such individuals, either
party may submit the dispute to any court of competent jurisdiction of resolution. Except as
explicitly set forth below, pre-clinical milestone payments shall be payable on only one Active
Compound per Myogen Target or Collaboration Target and clinical milestone payments shall be payable
only once with respect to a particular Myogen Compound, Collaboration Compound or NIBRI Compound,
even though that Myogen Compound, Collaboration Compound or NIBRI Compound may be subsequently
developed for indications other than those for which regulatory approval was initially sought. In
the event that a Myogen Compound, Collaboration Compound or NIBRI Compound fails in development,
any milestone payments previously paid with respect to such Myogen Compound, Collaboration Compound
or NIBRI Compound shall be fully creditable toward the same milestone due with respect to another
Myogen Compound, Collaboration Compound or NIBRI Compound advanced as a lead Compound in place of
the

 [..**..] Confidential Treatment Requested

19

 

failed Compound that acts on the same Myogen Target or Collaboration Target. NIBRI may deduct
from any milestone payments otherwise due to Myogen under this Section 3.5 the amount of any
withholding and similar taxes required under applicable law to be withheld from such payments and
paid to applicable tax authorities.

     The schedule below corresponds to an identical schedule in the License Agreement for all
Myogen Compounds, Collaboration Compounds or NIBRI Compounds other than HDAC Inhibitor Compounds
(the milestone payments for which will be as specified in Section 3.6 below) with respect to
milestones achieved in the Field; payments made pursuant to this Agreement prior to exercise of an
Option shall be treated as payments made under the applicable License Agreement.

	 	 	 	 	 	 	 
	 	 	 	 	 	 	MILESTONE
	DEVELOPMENTAL MILESTONE:	 	PAYMENT
	Pre-Clinical Milestones:	 	 
	 
	 	 	 	 	 	 
	 

	 	•
	 	Validation of high-throughput assays*
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	In vitro validation of lead compound*
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	In Vivo Validation of lead compound or
use of the lead compound as a starting point for
medicinal chemistry and/or SAR exploration*
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Completion of Tox/ADME screening and
preclinical candidate determination*
	 	[..**..]

 [..**..] Confidential Treatment Requested

20

 

	 	 	 	 	 	 	 
	 	 	 	 	 	 	MILESTONE
	DEVELOPMENTAL MILESTONE:	 	PAYMENT
	Clinical Milestones:	 	 
	 
	 	 	 	 	 	 
	 

	 	•	 	IND filing
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Initiation of Phase II clinical
evaluation
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Initiation of Phase III clinical studies
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Regulatory filing in the U.S.
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	First regulatory filing in the E.U.
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	Regulatory Approval in the U.S.
	 	[..**..]
	 
	 	 	 	 	 	 
	 

	 	•
	 	First Regulatory Approval in the E.U.
	 	[..**..]

 

			
	*	 	Criteria for determining the achievement of any Milestone have been established by the JSC
and distributed to the parties under separate cover.

     3.6. Milestone Payments for HDAC Inhibitor Compounds.

     NIBRI shall make milestone payments to Myogen in accordance with this Section 3.6 with
respect to each HDAC Inhibitor Compound within [..**..] days of the achievement of
such milestone. Except as explicitly set forth below, pre-clinical milestone payments
shall be payable on only one Active Compound per Myogen Target or Collaboration Target, and
clinical milestones shall be payable only once on a particular Active Compound, even though
that Active Compound may be subsequently developed for indications other than those for
which regulatory approval was initially sought. In the event that an Active Compound fails
in development, any milestone payments previously paid with respect to such Active Compound
shall be fully creditable toward the same milestone due with respect to another Active
Compound that acts on the same Myogen Target or Collaboration Target. NIBRI may deduct
from any milestone payments otherwise due to Myogen under this Section 3.6 the amount of
any withholding and similar taxes required under applicable law to be withheld from such
payments and paid to applicable tax authorities.

[..**..] Confidential Treatment Requested

21

 

     The schedule below corresponds to an identical schedule in the License Agreement for
all HDAC Inhibitor Compounds with respect to milestones achieved in the Field; payments
made pursuant to this Agreement prior to exercise of an Option shall be treated as payments
made under the applicable License Agreement.

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Future	 	 
	 	 	 	 	 	 	Prior Clinical	 	NIBRI	 	Collaboration
	 	 	 	 	 	 	NIBRI HDAC	 	HDAC	 	HDAC
	DEVELOPMENTAL	 	Inhibitor	 	Inhibitor	 	Inhibitor
	MILESTONE:	 	Compounds*	 	Compounds*	 	Compounds
	Pre-Clinical Milestones:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	Validation of high-throughput
assays**
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	In vitro validation of lead
compound**
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	In Vivo Validation of lead
compound or use of the lead compound as a
starting point for medicinal chemistry
and/or SAR exploration**
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	Additional payment at the earlier
of In Vivo Validation or second
(2nd) anniversary of the
Amendment Date***
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	Completion of Tox/ADME screening
and preclinical candidate determination**
	 	[..**..]
	 	[..**..]
	 	[..**..]

[..**..] Confidential Treatment Requested

22

 

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Future	 	 
	 	 	 	 	 	 	Prior Clinical	 	NIBRI	 	Collaboration
	 	 	 	 	 	 	NIBRI HDAC	 	HDAC	 	HDAC
	DEVELOPMENTAL	 	Inhibitor	 	Inhibitor	 	Inhibitor
	MILESTONE:	 	Compounds*	 	Compounds*	 	Compounds
	Clinical Milestones:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	IND filing
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	Initiation of Phase II clinical
evaluation
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	Initiation of Phase III clinical
studies
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	Regulatory filing in the U.S.
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	First regulatory filing in the
E.U.
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	Regulatory Approval in the U.S.
	 	[..**..]
	 	[..**..]
	 	[..**..]
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	•
	 	First Regulatory Approval in the
E.U.
	 	[..**..]
	 	[..**..]
	 	[..**..]

 
 

			
	*	 	For purposes of determining the milestone payments applicable to a NIBRI HDAC
Inhibitor Compound in the above table: (i) a “Prior Clinical NIBRI HDAC Inhibitor
Compound” means a NIBRI HDAC Inhibitor Compound for which NIBRI or its Affiliates (or,
if applicable, the licensor or assignor to NIBRI or its Affiliates if the compound was
licensed to or acquired by NIBRI or its Affiliates) have submitted an IND with the FDA and
initiated a Phase I Clinical Trial covering such compound prior to the Amendment Date (or,
in the case of licensed or acquired compounds, prior to the date of such license or
acquisition); and (ii) a “Future NIBRI HDAC Inhibitor Compound” means any NIBRI
HDAC Inhibitor Compound other than a Prior Clinical NIBRI HDAC Inhibitor Compound.
	 
	**	 	Criteria for determining the achievement of any Milestone have been established by
the JSC and distributed to the parties under separate cover.
	 
	***	 	For the avoidance of doubt, this milestone is payable only once.

ARTICLE IV

License, Development and Commercialization Rights

 [..**..] Confidential Treatment Requested

23

 

     4.1. Evaluation License.

          4.1.1. Myogen hereby grants to NIBRI and its Affiliates a non-sublicensable (except to the
extent required to engage any academic collaborators or contractors used in connection with the
Research Program by either party) license in the Territory and in the Field, to use and have used
any and all Myogen Technology, Myogen Compounds, Myogen Targets, Collaboration Targets, and
Collaboration Compounds solely for the purpose of performing the Research Program. The license
granted by Myogen is exclusive solely to the extent provided in Section 4.2.2.

          4.1.2. NIBRI hereby grants to Myogen and its Affiliates a non-exclusive license in the
Territory to use and have used any and all NIBRI Technology, NIBRI Compounds, Collaboration
Targets, and Collaboration Compounds solely for the purpose of performing the Research Program with
respect to the High Priority Targets and to use and have used only Collaboration Technology and
Collaboration Compounds for conducting research and development activities within the Research
Program on any Low Priority Targets or Extra-Collaboration Targets.

     4.2. Option to License.

          4.2.1. NIBRI shall have the exclusive right (the “Option”) to license any and all
Active Compounds, together with their underlying Myogen Targets or Collaboration Targets, as
Development Candidates, for development and commercialization of products with respect to any and
all human or veterinary health care uses and any and all agricultural uses under the terms and
conditions set forth in this Agreement and the applicable License Agreement.

          4.2.2. Myogen will not, at any time prior to the expiration of an Option in accordance with
Section 4.5, grant to any Third Party rights within the Field to any applicable Myogen Technology,
Myogen Compounds, Myogen Targets, Collaboration Targets, or Collaboration Compounds nor will Myogen
enter into any collaboration within the Field with a Third Party with respect to any of the
foregoing. The latter restriction shall not apply to Extra-Collaboration Targets, as defined
below, or the Active Compounds having a therapeutic effect on such Extra-Collaboration Targets, if
NIBRI’s right of first negotiation has lapsed or failed to

 [..**..] Confidential Treatment Requested

24

 

result in a completed transaction between Myogen and NIBRI, despite the good faith efforts of
the parties.

     4.3. Prioritization of Compounds.

          For purposes of this Agreement and the Research Program, the JSC shall classify all Myogen
Targets and Collaboration Targets in one of the following three categories:

          4.3.1. “High Priority Targets” are those Myogen Targets and Collaboration Targets the
study of which, and the allocation of resources to which, the JSC has established as a high
priority of the Research Program. In the case of Active Compounds related to such High Priority
Targets:

	 	(a)	 	NIBRI shall make payments with respect to all research
milestones in accordance with Section 3.5 above, [..**..];
	 
	 	(b)	 	[..**..] shall be payable; and
	 
	 	(c)	 	NIBRI may exercise its Option to license an Active Compound
relating to a High-Priority Target in accordance with Section 4.4 prior to the
expiration of such Option as set forth in Section 4.5.1.

          4.3.2. “Low Priority Targets” are those Myogen Targets and Collaboration Targets the
study of which, and the allocation of resources to which, the JSC has determined are not an
immediate priority but could prove to be of importance in the Research Program. Myogen may
continue to study such Low Priority Targets and Active Compounds relating to such Targets using its
own resources. In the case of Active Compounds related to such Low Priority Targets:

	 	(a)	 	[..**..] shall be payable so long as a Low Priority
Target retains that status;
	 
	 	(b)	 	At any time during the Term, but in any case no later than
[..**..] after In Vivo Validation of a Active Compound in connection
with such Low Priority Target, the JSC will elect either to elevate its status
to that of a High Priority Target or to lower its status to an
Extra-Collaboration

[..**..] Confidential Treatment Requested

25

 

	 	 	 	Target, as defined below. In the event the JSC elects to elevate its status
to that of a High Priority Target, all payments associated with all
previously achieved milestones shall be due and payable within thirty (30)
days of such JSC election, subject to Section 12.16;
	 
	 	(c)	 	NIBRI may exercise its Option to license an Active Compound
relating to a Low-Priority Target in accordance with Section 4.4 prior to the
expiration of such Option as set forth in Section 4.5.2. In the event NIBRI
exercises its Option, payments associated with all previously achieved
milestones shall, solely to the extent not already paid by NIBRI, be due and
payable within [..**..] of execution of the respective License
Agreement, subject to Section 12.16; and
	 
	 	(d)	 	If NIBRI does not exercise its Option with respect to an Active
Compound relating to a Low-Priority Target prior to the expiration of such
Option as set forth in Section 4.5.2, then such Low Priority Target shall
become an Extra-Collaboration Target upon the expiration of such Option and, to
the extent such Active Compound is a Myogen Compound or a Collaboration
Compound, then such Compound shall become an Extra-Collaboration Compound.

          4.3.3. “Extra-Collaboration Targets” and “Extra-Collaboration Compounds” are
those Myogen Targets and Myogen Compounds and Collaboration Compounds the study of which the JSC
determines not to pursue in connection with the Research Program, or which subsequently become
Extra-Collaboration Targets or Extra-Collaboration Compounds pursuant to Sections 4.3.2(b) or
4.3.2(d). In the case of Extra-Collaboration Targets and Extra-Collaboration Compounds:

	 	(a)	 	Myogen may continue to study, develop and/or commercialize such
Extra-Collaboration Targets and Extra-Collaboration Compounds using its own
resources, subject to its continued commitment to the resource levels

[..**..] Confidential Treatment Requested

26

 

	 	 	 	specified in the Work Plans for the High Priority Targets and the periodic
review of the JSC;

	 	(b)	 	[..**..] shall be payable by NIBRI with respect to
Active Compounds in connection with Extra-Collaboration Targets; and

	 	(c)	 	In the event that Myogen contemplates collaborating with a
Third Party with respect to development and/or commercialization of an Active
Compound acting on an Extra-Collaboration Target in the Field, Myogen shall
give NIBRI written notice of the same. Within [..**..] of receipt of
such notice, NIBRI shall inform Myogen in writing as to whether it wishes to
negotiate in good faith a collaboration between NIBRI and Myogen for the same
purposes. If NIBRI so informs Myogen, then the parties shall have
[..**..] to negotiate a transaction in good faith. If the parties are
unable to consummate a transaction within such period (or such longer period as
the parties may agree to in writing), then Myogen may enter into a Third Party
transaction with respect to the Extra-Collaboration Target or
Extra-Collaboration Compound. The right of first negotiation set out in this
Section 4.3.3(c) shall survive [..**..] beyond any early termination
of this Agreement under Section 9.4 or [..**..] after expiration of
this Agreement; provided, however, that if any Active Compound
or Extra-Collaboration Target is in development at the time of the termination
of this right of first negotiation and has not attained In Vivo Validation,
NIBRI may extend the right for a period of up to [..**..] or until
[..**..] after In Vivo Validation is achieved, whichever occurs first,
by paying to Myogen an option fee of [..**..] for each such
Extra-Collaboration Target or Active Compound.

     4.4. Exercise of an Option.

          NIBRI may exercise an Option by delivery to Myogen of written notice of exercise specifying
the Development Candidate as to which such Option is being exercised (an

[..**..] Confidential Treatment Requested

27

 

“Exercise Notice”) prior to the expiration of such Option in accordance with Section
4.5. As promptly as practicable following Myogen’s receipt of a timely Exercise Notice, the
parties shall execute a License, Development and Commercialization Agreement identical in substance
to Exhibit A-1 hereto (with respect to any Development Candidate other than an HDAC
Inhibitor Compound) or Exhibit A-2 hereto (with respect to any Development Candidate that
is an HDAC Inhibitor Compound), the terms of which are incorporated by reference into, and are a
part of, this Agreement, pursuant to which NIBRI will use commercially reasonable efforts (as
defined in the License Agreement), to further develop and commercialize the Development Candidate.
Development of each Development Candidate shall proceed as soon as practicable after the Option is
exercised, in accordance with the terms of the License Agreement.

     4.5. Expiration of Options. Options expire as follows:

          4.5.1 An Option on an Active Compound relating to a High Priority Target will expire on the
first to occur of:

	 	(a)	 	[..**..];
	 
	 	(b)	 	[..**..];
	 
	 	(c)	 	[..**..]; or
	 
	 	(d)	 	[..**..].

          4.5.2 An Option on an Active Compound relating to a Low Priority Target will expire at the
first to occur of:

	 	(a)	 	[..**..];
	 
	 	(b)	 	[..**..];
	 
	 	(c)	 	[..**..]; or
	 
	 	(d)	 	[..**..].

[..**..] Confidential Treatment Requested

28

 

     4.6. Rights to Compounds.

          (a) NIBRI agrees that, during the term of this Agreement and after expiration or termination
of this Agreement, NIBRI and its Affiliates will not develop and/or commercialize (either by
themselves or through a Third Party) in the Field an Active Compound that is a NIBRI Compound or
Collaboration Compound except under a License Agreement. In addition, NIBRI agrees that, during
the term of this Agreement and after termination of this Agreement, NIBRI and its Affiliates will
not develop and/or commercialize (either by themselves or through a Third Party) a compound that is
a Myogen Compound except in the Field under a License Agreement.

          (b) Myogen agrees that, during the term of this Agreement and after expiration or termination
of this Agreement, Myogen and its Affiliates will not develop and/or commercialize (either by
themselves or through a Third Party) a compound that is a NIBRI Compound without the prior consent
of NIBRI, which may be withheld in NIBRI’s sole discretion.

          (c) Subject solely to the terms of this Agreement and any License Agreement executed by the
Parties, Myogen hereby grants to NIBRI and its Affiliates a fully paid, exclusive, royalty-free,
perpetual, world-wide license to use, have used, develop, make, manufacture and sell all NIBRI
Compounds outside of the Field. Subject solely to the terms of this Agreement and any License
Agreement executed by the Parties, NIBRI hereby grants to Myogen and its Affiliates a fully paid,
exclusive, royalty-free, perpetual, world-wide license to use, have used, develop, make,
manufacture and sell all Myogen Compounds outside of the Field and, after expiration of NIBRI’s
Option with respect to any such Myogen Compound, inside the Field. The foregoing licenses shall
include the right to sublicense.

ARTICLE V

Confidentiality

     5.1. Undertaking.

          During the term of this Agreement, each party (the “Receiving Party”) shall keep
confidential, and other than as provided herein shall not use or disclose, directly or indirectly,

 [..**..] Confidential Treatment Requested

29

 

any trade secrets, confidential or proprietary information, or any other knowledge, information,
documents or materials, owned, developed or possessed by the other party (the “Proprietary
Party”), whether in tangible or intangible form, the confidentiality of which such Proprietary
Party takes reasonable measures to protect, including but not limited to Collaboration Technology.

	 	(a)	 	The Receiving Party shall take any and all lawful measures to
prevent the unauthorized use and disclosure of such information, and to prevent
unauthorized persons or entities from obtaining or using such information.
	 
	 	(b)	 	The Receiving Party further agrees to refrain from directly or
indirectly taking any action which would constitute or facilitate the
unauthorized use or disclosure of such information. The Receiving Party may
disclose such information to its Affiliates, officers, employees and agents, to
authorized licensees and sublicensees, and to subcontractors in connection with
the development or manufacture of Compounds or Development Candidates, as
applicable, to the extent necessary to enable such parties to perform their
obligations hereunder or under the applicable license, sublicense or
subcontract, as the case may be; provided, however, that such
Affiliates, officers, employees, agents, licensees, sublicensees and
subcontractors have entered into appropriate confidentiality agreements for
secrecy and non-use of such information which by their terms shall be
enforceable by injunctive relief at the instance of the Proprietary Party.
	 
	 	(c)	 	The Receiving Party shall be liable for any unauthorized use
and disclosure of such information by its Affiliates, officers, employees and
agents and any such sublicensees and subcontractors.

     5.2. Exceptions.

          Notwithstanding the foregoing, the provisions of Section 5.1 hereof shall not apply to
knowledge, information, documents or materials that the Receiving Party can conclusively establish:

[..**..] Confidential Treatment Requested

30

 

	 	(a)	 	have entered the public domain without the Receiving Party’s
breach of any obligation owed to the Proprietary Party;
	 
	 	(b)	 	have become known to the Receiving Party from a source other
than the Proprietary Party, other than by breach of an obligation of
confidentiality owed to the Proprietary Party; or
	 
	 	(c)	 	are independently developed by the Receiving Party without
breach of this Agreement, without reference to or reliance upon knowledge,
information or materials of the disclosing party as established by written
records.

          In addition, a Receiving Party may, notwithstanding the obligations of Section 5.1, disclose
knowledge, information, documents or materials that the Receiving Party can conclusively establish:

	 	(i)	 	are permitted to be disclosed by the prior written consent of
the Proprietary Party; or
	 
	 	(ii)	 	are required to be disclosed by the Receiving Party to comply
with applicable laws or regulations, to defend or prosecute litigation or to
comply with governmental regulations, provided that the Receiving Party
provides prior written notice of such disclosure to the Proprietary Party and
takes reasonable and lawful actions to avoid or minimize the degree of such
disclosure.

     5.3. Publicity.

          The parties will agree upon the timing and content of any press release or other public
communications relating to this Agreement and the transactions contemplated herein.

	 	(a)	 	Except to the extent already disclosed in a press release or
other public communication, no public announcement concerning the existence or
the terms of this Agreement or concerning the transactions described herein
shall be made, either directly or indirectly, by Myogen or NIBRI, except as may
be legally required by applicable laws, regulations, or judicial

[..**..] Confidential Treatment Requested

31

 

	 	 	 	order, without first obtaining the approval of the other party and agreement
upon the nature, text, and timing of such announcement, which approval and
agreement shall not be unreasonably withheld.
	 
	 	(b)	 	The party desiring to make any such public announcement shall
provide the other party with a written copy of the proposed announcement in
sufficient time prior to public release to allow such other party to comment
upon such announcement, prior to public release.

     5.4. Survival.

          The provisions of this Article V shall survive the termination of this Agreement.

ARTICLE VI

Publication

     6.1. Publication.

          Each of NIBRI and Myogen, and their respective Affiliates, agree not to publish or publicly
present any results, data, or scientific findings with respect to the Research Program (except in
connection with filings with the Food and Drug Administration or another similar governmental
entity) without the prior written consent of the JSC. In the event of information already within
the public domain, consent shall not be unreasonably withheld if sought at least thirty (30) days
prior to planned submission for publication or oral presentation. In all other instances during
the term of this Agreement, publication shall be presumed to be impermissible until the JSC shall
have determined, in its sole judgment, that the intellectual property rights of the parties in such
information first shall have been adequately protected, whether by foreign filing of Patents or
otherwise. To the extent that a proposed publication of any results, data, or scientific findings
with respect to the Research Program is subject to the terms of Myogen’s existing license
agreements, sponsored research agreements or material transfer agreements with the University of
Texas Southwestern Medical Center, the University of North Texas Health Sciences Center or the
University of Colorado, the procedure for publication of such results, data or findings will be as
specified in those agreements.

[..**..] Confidential Treatment Requested

32

 

ARTICLE VII

Indemnification

     7.1. Indemnification by Myogen.

          Myogen will indemnify, defend, and hold NIBRI and its Affiliates, their respective employees,
shareholders, officers and directors and the successors, heirs and assigns of each of them,
harmless against any loss, damages, action, suit, claim, demand, liability, expense, bodily injury,
death or property damage (a “Loss”), that may be brought, instituted or arise against or be
incurred by such persons to the extent such Loss is based on or arises out of: (a) the breach by
Myogen of any of its covenants, representations or warranties set forth in this Agreement; or (b)
the development or commercialization of a Development Candidate by Myogen, but excluding any such
Loss that is caused by the negligent or reckless acts or omissions of NIBRI.

     7.2. Indemnification by NIBRI.

          NIBRI will indemnify, defend, and hold Myogen, and its Affiliates, and their respective
employees, shareholders, officers and directors and the successors, heirs, and assigns of each of
them, harmless against any Loss that may be brought, instituted or arise against or be incurred by
such persons to the extent such Loss is based on or arises out of: (a) the breach by NIBRI of any
of its covenants, representations or warranties set forth in this Agreement; or (b) the development
or commercialization of a Development Candidate by NIBRI, but excluding any such Loss that is
caused by the negligent or reckless acts or omissions of Myogen.

     7.3. Claims Procedures.

          Each Party entitled to be indemnified by the other Party (an “Indemnified Party”)
pursuant to Section 7.1 or 7.2 hereof shall give notice to the other Party (an “Indemnifying
Party”) promptly after such Indemnified Party has actual knowledge of any threatened or
asserted claim as to which indemnity may be sought, and shall permit the Indemnifying Party to
assume the sole control of the defense of any such claim or any litigation resulting therefrom;
provided, however:

[..**..] Confidential Treatment Requested

33

 

	 	(a)	 	That counsel for the Indemnifying Party, who shall conduct the
defense of such claim or any litigation resulting therefrom, shall be approved
by the Indemnified Party (whose approval shall not unreasonably be withheld)
and the Indemnified Party may participate in such defense at such party’s
expense (unless: (i) the employment of counsel by such Indemnified Party has
been authorized by the Indemnifying Party; or (ii) the Indemnified Party shall
have reasonably concluded that there may be a conflict of interest between the
Indemnifying Party and the Indemnified Party in the defense of such action, in
each of which cases the Indemnifying Party shall pay the reasonable fees and
expenses of one law firm serving as counsel for the Indemnified Party, which
law firm shall be subject to approval, not to be unreasonably withheld, by the
Indemnifying Party); and
	 
	 	(b)	 	The failure of any Indemnified Party to give notice as provided
herein shall not relieve the Indemnifying Party of its obligations under this
Agreement to the extent that the failure to give notice did not result in harm
to the Indemnifying Party or materially compromise the defense of such claim.
	 
	 	(c)	 	No Indemnifying Party, in the defense of any such claim or
litigation, shall consent to entry of any judgment or enter into any
settlement, except with the approval of each Indemnified Party (which approval
shall not be unreasonably withheld), except a settlement which imposes only a
monetary obligation on the Indemnifying Party and which includes as an
unconditional term thereof the giving of a release from all liability in
respect to such claim or litigation by the claimant or plaintiff to the
Indemnified Party.
	 
	 	(d)	 	Each Indemnified Party shall furnish such information or
reasonable assistance regarding itself or the claim in question as an
Indemnifying Party may reasonably request in writing and shall be reasonably
required

[..**..] Confidential Treatment Requested

34

 

	 	 	 	in connection with the defense of such claim and litigation resulting therefrom.

     7.4. Compliance.

          The parties shall comply fully with all applicable laws and regulations in connection with
their respective activities under this Agreement.

ARTICLE VIII

Intellectual Property Rights

     8.1. Ownership.

          8.1.1. Subject to any licenses explicitly granted under this Agreement or a License Agreement,
each party shall retain its intellectual property rights in all Compounds and Technology Controlled
by it on the Effective Date or otherwise arising outside of the Research Program.

          8.1.2. Any new invention created or any new Know-How generated exclusively by a party or its
Affiliate (directly or through others acting on its behalf) prior to and during the term of this
Agreement shall be owned by such party; provided, however, that if such new
invention or new Know-How of Myogen is necessary to NIBRI’s exercise of its license rights under a
License Agreement, then the definition of Myogen Technology will be deemed to include such new
invention or new Know-How that are included within the licenses granted to NIBRI under the License
Agreement.

          8.1.3. Any new invention created jointly by the parties shall be jointly owned (a “Joint
Invention”), and the respective rights of the parties with respect to the Joint Invention shall
be determined in accordance with United States patent law as it applies to issues of joint
ownership of intellectual property as of the Effective Date.

          8.1.4. NIBRI will retain ownership of all intellectual property rights in and to the NIBRI
Compounds and Myogen will retain all intellectual property rights in and to the Myogen Compounds.
Myogen will take all reasonable actions requested by NIBRI, including execution

[..**..] Confidential Treatment Requested

35

 

of appropriate transfer documents, patent filings and applications for registration, to
perfect NIBRI’s ownership interests in and to the NIBRI Compounds. NIBRI will take all reasonable
actions requested by Myogen, including execution of appropriate transfer documents, patent filings
and applications for registration, to perfect Myogen’s ownership interests in and to the Myogen
Compounds, including, without limitation, transfer and assignment of all right, title and interest
in the following Patent and all related Patents: United States Patent Application No. 60/752,145
filed by NIBRI on December 20, 2005.

     8.2. Preparation and Costs.

          Myogen shall take responsibility and pay for the preparation, filing, prosecution and
maintenance of all Myogen Patents and, subject to Section 8.3, any Joint Inventions abandoned by
NIBRI, and NIBRI shall take responsibility and pay for the preparation, filing, prosecution and
maintenance of: (a) all NIBRI Patents; (b) any patents and patent applications claiming Joint
Inventions; and (c) all Patents related to Development Candidates. Myogen shall provide the JSC
with periodic reports listing, by name, Myogen Patents filed in the United States and other
jurisdictions, along with a general summary of the claims made and the jurisdictions of filing. In
good time, before the deadline for foreign filing of any patent application filed in the United
States, Myogen will notify NIBRI whether it intends to foreign file such patent application, and if
it intends to do so, in what countries it proposes to foreign file. The parties hereby agree that
to the extent legally possible and commercially reasonable, the responsible party shall, at a
minimum, prepare, file, prosecute and maintain patent coverage as described in this section in the
countries listed in Schedule 8.2 hereto. NIBRI and Myogen agree to use all commercially reasonable
efforts to secure patent protection on any intellectual property created during the Research
Program. NIBRI will consult with Myogen on the drafting and prosecution of patent applications on
Joint Inventions that relate to the Myogen Targets and/or the Collaboration Targets in the United
States and in countries listed in Schedule 8.2 that are commercially viable, and, to the extent
reasonably practicable under the circumstances, give Myogen an opportunity to comment and suggest
revisions to any patent application covering such Joint Inventions.

[..**..] Confidential Treatment Requested

36

 

     8.3. Discontinuation.

          The party initially responsible under Section 8.2 for the preparation, filing, prosecution and
maintenance of a particular Patent shall give at least thirty (30) days advance notice to the other
party of any decision to cease preparation, filing, prosecution and maintenance of that Patent in a
jurisdiction listed on Schedule 8.2 hereof. Discontinuation may be elected on a country-by-country
basis or for a Patent application or Patent series in total. In such case, the other party may
elect at its sole discretion to continue preparation, filing, and prosecution or maintenance of the
discontinued Patent at its sole expense.

     8.4. Advice to JSC on Intellectual Property Matters.

          The JSC shall appoint an intellectual property subcommittee comprising appropriate legal
counsel from each party to advise the JSC on intellectual property protection issues. Such
subcommittee shall, at the request of the JSC, report at least quarterly to the JSC.

ARTICLE IX

Term and Termination

     9.1. Term.

          This Agreement will extend until the termination (including any early termination hereunder)
of the Research Program (including any extension thereof) in accordance with Section 2.2, unless
earlier terminated by either party hereto in accordance with this Agreement, or unless extended by
mutual agreement of the parties.

     9.2. Termination of the Research Program by NIBRI for Cause.

          Upon written notice to Myogen, NIBRI may at its sole discretion unilaterally terminate the
Research Program and this Agreement upon the occurrence of any of the following events:

	 	(a)	 	Myogen shall breach any of its material obligations under this
Agreement or a License Agreement, and such breach shall not have been remedied
or steps initiated to remedy the same to NIBRI’s reasonable satisfaction,

[..**..] Confidential Treatment Requested

37

 

	 	 	 	within sixty (60) days after NIBRI sends written notice of breach to Myogen;
	 
	 	(b)	 	Myogen shall cease to function as a going concern by suspending
or discontinuing its business for any reason except for interruptions caused by
Force Majeure, strike, labor dispute or any other events over which it has no
control; or
	 
	 	(c)	 	Upon a sale, merger, consolidation, transfer, or other
reorganization of Myogen in which substantially all of the assets of Myogen are
transferred or in which the holders of Myogen’s capital stock immediately prior
to the transaction hold less than a majority of the capital stock of the
surviving entity subsequent to the transaction, in either case to an entity or
an Affiliate thereof reasonably conceived by NIBRI to be a NIBRI Competitor.

          In the event of any valid termination under this Section 9.2, NIBRI shall not be required to
make any payments under Section 3.3 hereof which are not due and payable prior to receipt by Myogen
of the notice of breach referenced under Section 9.2(a) or receipt by Myogen of the notice of
termination pursuant to Section 9.2(b), as the case may be. Notwithstanding the foregoing, any
License Agreement then in effect shall continue in effect unless it is expressly terminated in
accordance with its terms.

     9.3. Termination of the Research Program by Myogen for Cause.

          Myogen may at its sole discretion terminate the Research Program and this Agreement upon
written notice to NIBRI upon the occurrence of any of the following events:

	 	(a)	 	NIBRI shall breach any of its material obligations under this
Agreement or a License Agreement and such breach shall not have been remedied
or steps initiated to remedy the same to Myogen’s reasonable satisfaction,
within sixty (60) days after Myogen sends written notice of breach to NIBRI; or

[..**..] Confidential Treatment Requested

38

 

	 	(b)	 	NIBRI shall cease to function as a going concern by suspending
or discontinuing its business for any reason except for interruptions caused by
Force Majeure, strike, labor dispute or any other events over which it has no
control, and no Affiliate of NIBRI shall have assumed NIBRI’s function.

          Upon any termination under Section 9.3(a), all licenses and other rights (including Options)
granted hereunder shall also terminate. Notwithstanding the foregoing, any License Agreement then
in effect shall continue in effect unless it is expressly terminated in accordance with its terms.

     9.4. Early Termination of the Research Program by NIBRI.

          In the event that, in its reasonable, good faith judgment, the overall Research Program
(excluding the HDAC Inhibitor Research Program) is proceeding unsatisfactorily, NIBRI may in its
absolute discretion terminate its participation in and funding of the aspects of the Research
Program that are not the HDAC Inhibitor Research Program effective no earlier than eighteen (18)
months from the Effective Date, upon sixty (60) days’ prior written notice to Myogen. In the event
that, in its reasonable, good faith judgment, the HDAC Inhibitor Research Program is proceeding
unsatisfactorily, NIBRI may in its absolute discretion terminate its participation in and funding
of the HDAC Inhibitor Research Program effective no earlier than eighteen (18) months from the
Amendment Date, upon sixty (60) days’ prior written notice to Myogen. [..**..]

     9.5. Effect of Termination or Expiration.

          Except where explicitly provided elsewhere herein, termination of this Agreement for any
reason, or expiration of this Agreement, will not affect: (a) obligations which have accrued as of
the date of termination or expiration; and (b) obligations and rights which, expressly or from the
context thereof, are intended to survive termination or expiration of this Agreement, including but
not limited to obligations of confidentiality under Section 2.6.2 and Article V hereof, the
indemnification provisions of Article VII hereof and the intellectual property ownership and
information sharing provisions contained in Sections 2.6, 2.7, 4.6 and

[..**..] Confidential Treatment Requested

39

 

8.1. Except as otherwise provided hereunder, all licenses granted under this Agreement shall
terminate upon termination or expiration of this Agreement.

ARTICLE X

Representations and Warranties

     10.1. Representations and Warranties of Myogen.

          Myogen represents and warrants to NIBRI as follows:

	 	(a)	 	Authorization. This Agreement has been duly executed
and delivered by Myogen and constitutes the valid and binding obligation of
Myogen, enforceable against Myogen in accordance with its terms except as
enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency,
bankruptcy, reorganization, moratorium and other laws relating to or affecting
creditors’ rights generally and by general equitable principles. The
execution, delivery and performance of this Agreement have been duly authorized
by all necessary action on the part of Myogen, its officers and directors. No
provision of this Agreement violates any other agreement that Myogen may have
with any other person or company, and Myogen acknowledges that NIBRI has relied
on that representation in entering into this Agreement.
	 
	 	(b)	 	Myogen Controlled Rights. As of the Effective Date,
Myogen owns or possesses adequate licenses or other rights to use all Myogen
Technology relating to the Myogen Compounds and Myogen Targets and to grant the
licenses and perform the obligations contemplated herein, except to the extent
that Myogen’s agreements with Third Party licensors contain restrictions on
further sublicense by NIBRI. The granting of an Option to NIBRI hereunder does
not violate any right known to Myogen of any Third Party.

[..**..] Confidential Treatment Requested

40

 

	 	(c)	 	Third Party Patents. Except as disclosed in writing
between the parties to this Agreement or their respective agents, as of the
Effective Date, to Myogen’s knowledge there are no issued patents or pending
patent applications that, if issued, would be infringed by the development,
manufacture, use or sale of any Myogen Compound or Myogen Target, as
applicable, pursuant to this Agreement.

     10.2. Representations and Warranties of NIBRI.

          NIBRI represents and warrants to Myogen that this Agreement has been duly executed and
delivered by NIBRI and constitutes the valid and binding obligation of NIBRI, enforceable against
NIBRI in accordance with its terms except as enforceability may be limited by bankruptcy,
fraudulent conveyance, insolvency, bankruptcy, reorganization, moratorium and other laws relating
to or affecting creditors’ rights generally and by general equitable principles. The execution,
delivery and performance of this Agreement have been duly authorized by all necessary action on the
part of NIBRI, its officers and directors. No provision of this Agreement violates any other
agreement that NIBRI may have with any other person or company, and NIBRI acknowledges that Myogen
has relied on that representation in entering into this Agreement.

ARTICLE XI

Dispute Resolution

     11.1. Governing Law, and Jurisdiction.

          This Agreement shall be governed and construed in accordance with the internal laws of the
Commonwealth of Massachusetts.

     11.2. Dispute Resolution Process.

          Except with respect to any matters under the purview of the JSC pursuant to Section 2.8.1, and
except for any claim or controversy relating to a Critical Issue pursuant to Section 2.8.2 and
Section 11.3, in the event of any controversy or claim arising out of or relating

 [..**..] Confidential Treatment Requested

41

 

to the legal rights and remedies of the parties arising out of this Agreement, the parties
shall, and either party may, initially refer such dispute to the JSC, and failing mutually
acceptable resolution of the controversy or claim within thirty (30) days after such referral, the
matter shall be referred to the President and Chief Executive Officer of Myogen and the President
and Chief Executive Officer of NIBRI who shall, as soon as practicable, attempt in good faith to
resolve the controversy or claim. If such controversy or claim is not resolved within sixty (60)
days of the date of initial referral of the matter to the JSC, either party may submit the dispute
to any court of competent jurisdiction for resolution.

     11.3. Dispute Resolution Process for Critical Issues.

          In the event of any controversy or claim arising out of or relating to a Critical Issue which
the JSC is unable to resolve under Section 2.8.2, the parties shall refer the matter to the
President and Chief Executive Officer of Myogen and the President and Chief Executive Officer of
NIBRI who shall attempt in good faith and using their best efforts to resolve the controversy or
claim within sixty (60) days of the date of initial referral of the matter from the JSC. If such
controversy or claim is not resolved within sixty (60) days, then Myogen may, at its election,
either: (a) accept the final position of the President and Chief Executive Officer of NIBRI with
respect to such matter; or (b) terminate this Agreement on thirty (30) days’ written notice,
subject to the provisions of Section 9.5. Section 9.4 shall not apply to any termination of this
Agreement by Myogen pursuant to the immediately-preceding subsection (b).

[..**..] Confidential Treatment Requested

42

 

ARTICLE XII

Miscellaneous Provisions

     12.1. Waiver.

          No provision of this Agreement may be waived except in writing by both parties hereto. No
failure or delay by either party hereto in exercising any right or remedy hereunder or under
applicable law will operate as a waiver thereof, or a waiver of any right or remedy on any
subsequent occasion.

     12.2. Force Majeure.

          Neither party will be in breach hereof by reason of its delay in the performance of or failure
to perform any of its obligations hereunder, if that delay or failure is caused by strikes, acts of
God or the public enemy, riots, incendiaries, interference by civil or military authorities,
compliance with governmental priorities for materials, or any fault beyond its control or without
its fault or negligence.

     12.3. Severability.

          Should one or more provisions of this Agreement be or become invalid, then the parties hereto
shall attempt to agree upon valid provisions in substitution for the invalid provisions, which in
their economic effect come so close to the invalid provisions that it can be reasonably assumed
that the parties would have accepted this Agreement with those new provisions. If the parties are
unable to agree on such valid provisions, the invalidity of such one or more provisions of this
Agreement shall nevertheless not affect the validity of the Agreement as a whole, unless the
invalid provisions are of such essential importance for this Agreement that it may be reasonably
presumed that the parties would not have entered into this Agreement without the invalid
provisions.

     12.4. Government Acts.

          In the event that any act, regulation, directive, or law of a country or its government,
including its departments, agencies or courts, should make impossible or prohibit,

[..**..] Confidential Treatment Requested

43

 

restrain, modify or limit any material act or obligation of NIBRI or Myogen under this Agreement,
the party, if any, not so affected, shall have the right, at its option, to suspend or terminate
this Agreement as to such country, if good faith negotiations between the parties to make such
modifications therein as may be necessary to fairly address the impact thereof, are not successful
after a reasonable period of time in producing mutually acceptable modifications to this Agreement.

     12.5. Government Approvals.

          Each party will use commercially reasonable best efforts to obtain any government approval
required in its country of domicile to enable this Agreement to become effective, or to enable any
payment hereunder to be made, or any other obligation hereunder to be observed or performed. Each
party will keep the other informed of progress in obtaining any such government approval, and will
cooperate with the other party in any such efforts.

     12.6. Export Controls.

          This Agreement is made subject to any restrictions concerning the export of materials and
technology from the United States that may be imposed upon or related to either party to this
Agreement from time to time by the Government of the United States. Furthermore, each of NIBRI and
Myogen agrees that it will not export, directly or indirectly, any technical information acquired
from the other party under this Agreement or any products using such technical information to any
countries for which the United States Government or any agency thereof at the time of export
requires an export license or other governmental approval, without first obtaining the written
consent to do so from the Department of Commerce or other agency of the United States Government
when required by applicable statute or regulation.

     12.7. Assignment.

          This Agreement may not be assigned or otherwise transferred by either party without the prior
written consent of the other party; provided, however, that (a) NIBRI may assign
this Agreement, without the consent of Myogen: (i) to any of its Affiliates; or (ii) in
connection with the transfer or sale of all or substantially all of its assets or business or in
the event of its merger or consolidation with another company; and (b) Myogen may assign this

[..**..] Confidential Treatment Requested

44

 

Agreement, without the consent of NIBRI in connection with the transfer or sale of all or
substantially all of its assets or business or in the event of its merger or consolidation with
another Person, provided, however, that any such transaction in which a NIBRI
Competitor acquires all of Myogen’s assets or business or merges with Myogen, NIBRI may terminate
this Agreement pursuant to Section 9.2(c). Any purported assignment in contravention of this
Section 12.7 shall, at the option of the nonassigning party, be null and void and of no effect. No
assignment shall release either party from responsibility for the performance of any accrued
obligation of such party hereunder. This Agreement shall be binding upon and enforceable against
the successor to or any permitted assignees from either of the parties hereto.

     12.8. Affiliates.

          Each party may perform its obligations hereunder personally or through one or more Affiliates,
although each party shall nonetheless be solely responsible for the performance of its Affiliates.
Neither party shall permit any of its Affiliates to commit any act (including any act or omission)
which such party is prohibited hereunder from committing directly. The use of subcontractors by
either party shall not increase the financial obligations of the other party hereunder in any
respect.

     12.9. Counterparts.

          This Agreement may be executed in counterparts, each of which shall be deemed to be original
and both of which shall constitute one and the same Agreement.

     12.10. No Agency.

          Nothing herein contained shall be deemed to create an agency, joint venture, amalgamation,
partnership or similar relationship between NIBRI and Myogen and their respective Affiliates.
Notwithstanding any of the provisions of this Agreement, neither party to this Agreement shall at
any time enter into, incur, or hold itself out to Third Parties as having authority to enter into
or incur, on behalf of the other party, any commitment, expense, or liability whatsoever, and all
contracts, expenses and liabilities in connection with or relating to the obligations of each party
under this Agreement shall be made, paid, and undertaken exclusively by such party on its own
behalf and not as an agent or representative of the other.

[..**..] Confidential Treatment Requested

45

 

     12.11. Notice.

          All communications between the parties with respect to any of the provisions of this Agreement
will be sent to the addresses set out below, or to such other addresses as may be designated by one
party to the other by notice pursuant hereto, by prepaid, certified mail (which shall be deemed
received by the other party on the seventh business day following deposit in the mails), or by
facsimile transmission, or other electronic means of communication (which shall be deemed received
when transmitted), with confirmation by first class letter, postage pre-paid, given by the close of
business on or before the next following business day:

	 	 	 	 	 
	 	 	if to NIBRI, at:
	 
	 	 	 	 
	 

	 	 	 	Novartis Institutes for BioMedical Research, Inc.
	 

	 	 	 	400 Technology Square
	 

	 	 	 	Cambridge, Massachusetts 02139
	 

	 	 	 	Attention: Robert L. Thompson, Vice President and General Counsel
	 

	 	 	 	Fax: (617) 871-3354
	 
	 	 	 	 
	 	 	if to Myogen, at:
	 
	 	 	 	 
	 

	 	 	 	Myogen, Inc.
	 

	 	 	 	7575 W. 103rd Avenue
	 

	 	 	 	Westminster, Colorado 80021
	 

	 	 	 	Attention: J. William Freytag, President and Chief Executive Officer
	 

	 	 	 	Fax: (303) 410-6667
	 
	 	 	 	 
	 	 	with a copy to:
	 
	 	 	 	 
	 

	 	 	 	Myogen, Inc.
	 

	 	 	 	7575 W. 103rd Avenue
	 

	 	 	 	Westminster, Colorado 80021
	 

	 	 	 	Attention: Andrew D. Dickinson, Vice President and General Counsel
	 

	 	 	 	Fax: (303) 410-3350

     12.12. Headings.

          The paragraph headings are for convenience only and will not be deemed to affect in any way
the language of the provisions to which they refer.

[..**..] Confidential Treatment Requested

46

 

     12.13. Authority.

          The undersigned represent that they are authorized to sign this Agreement on behalf of the
parties hereto.

     12.14. Entire Agreement.

          This Agreement contains the entire understanding of the parties relating to the matters
referred to herein, and may only be amended by a written document, duly executed on behalf of the
respective parties.

     12.15. Notice of Pharmaceutical Side-Effects.

          During the term of this Agreement, the parties shall keep each other and the JSC promptly and
fully informed and will promptly notify appropriate authorities in accordance with applicable law,
after receipt of information with respect to any serious adverse event (as defined by the ICH
Harmonized Tripartite Guideline on Clinical Safety Data Management), directly or indirectly
attributable to the use or application of a Compound.

     12.16. Invoice Requirement.

          Any amounts payable to Myogen hereunder (except any royalty payments required to be made under
the provisions of Article IV of the License Agreement) shall be made within thirty (30) days after
receipt by NIBRI, or its nominee designated for that purpose in advance by NIBRI in writing to
Myogen, of an invoice covering such payment.

     12.17. Amendment and Restatement of Amended Agreement.

          The Original Agreement as amended by the Amendment is hereby amended in its entirety and
restated herein. Upon the execution of the Agreement by NIBRI and Myogen such amendment and
restatement shall be deemed to be effective upon the Effective Date except for those portions
herein which are effective as of the Amendment Date.

[Signature page follows]

[..**..] Confidential Treatment Requested

47

 

	 	 	 	 	 	 	 
	 	 	MYOGEN, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ J. William Freytag	 	 
	 

	 	 	 	 

J. William Freytag
	 	 
	 

	 	Title:
	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	 	 	NOVARTIS INSTITUTES FOR BIOMEDICAL
RESEARCH, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Jeremy Levin	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Jeremy Levin	 	 
	 

	 	Title:
	 	Global Head Strategic Alliances	 	 

[..**..] Confidential Treatment Requested

48

 

Schedule 1.30

Myogen Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Schedule 1.30 Myogen Patents
	PATENTS	 	Filing Date	 	App. No.	 	Country	 	Pat. No.	 	Issue Date	 	Subject Matter
	MYOG:004-USD1
	 	4/25/2000	 	09/558,472	 	U.S.	 	 	 	 	 	Alpha Myosin Heavy Chain Gene Therapy
	MYOG:004-USD2
	 	10/1/2001	 	09/969,086	 	U.S.	 	7,049,066	 	5/23/2006	 	Alpha Myosin Heavy Chain Therapeutic/Screening
	MYOG:004-USD3
	 	2/25/2005	 	11/067,502	 	U.S.	 	 	 	 	 	Alpha Myosin Heavy Chain Treatment
	MYOG:004-WO
	 	1/30/1998	 	PCT/US98/01983	 	PCT	 	 	 	 	 	Alpha Myosin Heavy Chain
	MYOG:004-CA
	 	7/29/1999	 	2,278,465	 	Canada	 	 	 	 	 	Alpha Myosin Heavy Chain
	MYOG:004-EP
	 	7/30/1999	 	98906089.2	 	Europe	 	 	 	 	 	Alpha Myosin Heavy Chain
	MYOG:004-JP
	 	7/30/1999	 	10-533182	 	Japan	 	 	 	 	 	Alpha Myosin Heavy Chain
	MYOG:005-US
	 	4/1/1998	 	09/053,293	 	U.S.	 	6,218,597	 	4/17/2001	 	Transgenic mice w/cardiac specific promoters
	MYOG:006-US
	 	9/26/1997	 	08/938,105	 	U.S.	 	6,353,151	 	3/5/2002	 	Transgeneic alpha myosin
	MYOG:006-EP
	 	5/24/1999	 	97943597.1	 	Europe	 	 	 	 	 	Alpha Myosin Transgenes
	MYOG:007-US
	 	5/26/1998	 	09/047,755	 	U.S.	 	6,203,776	 	3/20/2001	 	Methods for identifying adrenergic receptors
	MYOG:013-US
	 	6/19/1998	 	09/100,497	 	U.S.	 	5,998,458	 	12/7/1999	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-WO
	 	6/24/1998	 	PCT/US98/13442	 	PCT	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-AU
	 	1/6/2000	 	81740/98	 	Australia	 	731,656	 	7/19/2001	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-CA
	 	12/23/1999	 	2,295,094	 	Canada	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-EP
	 	1/25/2000	 	198,931,687	 	Europe	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:013-JP
	 	12/27/1999	 	11-505056	 	Japan	 	 	 	 	 	Positive inotrope + beta adrenergic receptor antagonist
	MYOG:020-US
	 	10/15/1998	 	09/173,798	 	U.S.	 	6,201,165	 	3/13/2001	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-WO
	 	10/16/1998	 	PCT/US98/21988	 	PCT	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-AU
	 	4/16/2000	 	10992/99	 	Australia	 	755428	 	8/16/2002	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-CA
	 	4/16/2000	 	2,315,244	 	Canada	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-EP
	 	4/16/2000	 	98953672.7	 	Europe	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-JP
	 	4/16/2000	 	2000-516026	 	Japan	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:020-MX
	 	4/14/2000	 	0003678	 	Mexico	 	 	 	 	 	CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenes
	MYOG:023-US
	 	10/15/1998	 	09/173,795	 	U.S.	 	6,673,768	 	1/6/2004	 	Calcineurin Therapies
	MYOG:024-US
	 	11/10/1999	 	09/438,075	 	U.S.	 	6,372,957	 	4/16/2002	 	MEF2 methods of treatment
	MYOG:024-USC1
	 	1/9/2002	 	10/043,658	 	U.S.	 	 	 	 	 	MEF2 screening methods
	MYOG:024-WO
	 	11/10/1999	 	PCT/US99/26725	 	PCT	 	 	 	 	 	MEF2
	MYOG:024-CA
	 	5/7/2001	 	2,350,086	 	Canada	 	 	 	 	 	MEF2
	MYOG:024-EP
	 	5/21/2001	 	99971848.9	 	Europe	 	 	 	 	 	MEF2
	MYOG:024-JP
	 	5/10/2001	 	2000-581187	 	Japan	 	 	 	 	 	MEF2
	MYOG:025-US
	 	10/15/1998	 	09/173,799	 	U.S.	 	6,657,104	 	12/2/2003	 	Calcineurin transgenics
	MYOG:026-US
	 	8/20/2000	 	09/643,206	 	U.S.	 	6,632,628	 	8/20/2000	 	HDAC screening and treatment
	MYOG:026-USD1
	 	8/20/2003	 	10/637,403	 	U.S.	 	 	 	 	 	HDAC transgenics
	MYOG:026-WO
	 	8/20/2000	 	PCT/US00/22958	 	PCT	 	 	 	 	 	Class II HDACs
	MYOG:026-CA
	 	2/14/2002	 	2,382,045	 	Canada	 	 	 	 	 	Class II HDACs
	MYOG:026-EP
	 	3/13/2002	 	00955805.7	 	Europe	 	 	 	 	 	Class II HDACs
	MYOG:026-JP
	 	2/19/2002	 	2001-518892	 	Japan	 	 	 	 	 	Class II HDACs
	 
	 	 	 	 	 	 	 	 	 	 	 	Muscle Ring Finger Proteins (MURFS) Screening and
	MYOG:028-US
	 	7/18/2001	 	09/908,988	 	U.S.	 	6,740,751	 	5/25/2004	 	Treatment
	 
	 	 	 	 	 	 	 	 	 	 	 	Muscle Ring Finger Proteins (MURFS) Screening and
	MYOG:028-USD1
	 	2/10/2004	 	10/775,627	 	U.S.	 	7,005,512	 	2/28/2006	 	Treatment
	MYOG:028-USD2
	 	2/10/2004	 	10/775,649	 	U.S.	 	issue fee	 	paid	 	Muscle Ring Finger Proteins (MURFS)
	MYOG:029-US
	 	4/16/1998	 	09/061,417	 	U.S.	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:029-WO
	 	10/16/1998	 	PCT/US98/21845	 	PCT	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:029-AU
	 	10/15/1998	 	98058/98	 	Australia	 	748334	 	9/12/2002	 	NF-AT3 inhibitors
	MYOG:029-CA
	 	4/10/2000	 	2,306,448	 	Canada	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:029-EP
	 	5/16/2000	 	9895233.7	 	Europe	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:029-JP
	 	4/17/2000	 	2000-516024	 	Japan	 	 	 	 	 	NF-AT3 inhibitors
	MYOG:034-US
	 	9/26/2002	 	10/256,221	 	U.S.	 	6,707,686	 	3/16/2004	 	HDAC Inhibitors

[..**..] Confidential Treatment Requested

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Schedule 1.30 Myogen Patents
	PATENTS	 	Filing Date	 	App. No.	 	Country	 	Pat. No.	 	Issue Date	 	Subject Matter
	MYOG:034-USC1
	 	3/16/2004	 	10/801,985	 	U.S.	 	6,946,441	 	9/20/2005	 	Inhibiting HDACs
	MYOG:034-USC2
	 	7/26/2005	 	11/190,074	 	U.S.	 	 	 	 	 	Inhibiting HDACs
	MYOG:034-USC3
	 	8/30/2005	 	11/215,844	 	U.S.	 	 	 	 	 	Inhibiting HDACs
	MYOG:034-EP
	 	9/27/2001	 	02/021678.8	 	Europe	 	1,297,851	 	1/26/2005	 	Inhibiting HDACs
	MYOG:034-EPD1
	 	1/25/2005	 	5001443	 	Europe	 	 	 	 	 	Inhibiting HDACs
	MYOG:034-JP
	 	9/27/2001	 	2002-284313	 	Japan	 	 	 	 	 	Inhibiting HDACs
	MYOG:035-US
	 	1/21/2003	 	10/348,598	 	U.S.	 	 	 	 	 	Hypertrophic Cell Line
	MYOG:036-US
	 	2/13/2001	 	09/782,953	 	U.S.	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:036-WO
	 	2/13/2001	 	PCT/US01/21662	 	PCT	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:036-CA
	 	1/24/2003	 	2,415,967	 	Canada	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:036-EP
	 	2/5/2003	 	1952568.2	 	Europe	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:036-JP
	 	12/26/2002	 	2002-509354	 	Japan	 	 	 	 	 	MCIP's screening, treatment, transgenics, antibodies
	MYOG:037-US
	 	8/20/2003	 	10/644,659	 	U.S.	 	 	 	 	 	STARS screening, treatment, transgenics, antibodies
	MYOG:044-US
	 	5/21/2003	 	10/848,820	 	U.S.	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-WO
	 	5/21/2003	 	PCT/US04/015715	 	PCT	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-AU
	 	5/21/2003	 	2004249114	 	Australia	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-BR
	 	5/21/2003	 	 	 	Brazil	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-CA
	 	5/21/2003	 	 	 	Canada	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-CN
	 	5/21/2003	 	 	 	China	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-EP
	 	5/21/2003	 	 	 	Europe	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-IN
	 	5/21/2003	 	 	 	India	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-JP
	 	5/21/2003	 	 	 	Japan	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:044-MX
	 	5/21/2003	 	 	 	Mexico	 	 	 	 	 	PKD (HDAC Kinase I)
	MYOG:045-US
	 	11/3/2004	 	10/980,612	 	U.S.	 	 	 	 	 	Alpha myocin modulating compound
‘R’ enatiomer
	MYOG:045-WO
	 	11/3/2004	 	PCT/US04/036569	 	PCT	 	 	 	 	 	Alpha myocin modulating compound
‘R’ enatiomer
	MYOG:046-US
	 	11/3/2004	 	10/980,605	 	U.S.	 	 	 	 	 	Alpha myocin modulating compound
‘S’ enatiomer
	MYOG:046-US
	 	11/3/2004	 	PCT/US04/036568	 	PCT	 	 	 	 	 	Alpha myocin modulating compound
‘S’ enatiomer
	MYOG:047-US
	 	11/13/2004	 	10/988,192	 	U.S.	 	 	 	 	 	TRP Channel
	MYOG:047-WO
	 	11/13/2004	 	PCT/US04/037858	 	PCT	 	 	 	 	 	TRP Channel
	MYOG:048-US
	 	12/23/2004	 	11/018,426	 	U.S.	 	 	 	 	 	5-HT2 receptors
	MYOG:048-WO
	 	12/23/2004	 	PCT/US04/042922	 	PCT	 	 	 	 	 	5-HT2 receptors
	MYOG:049-US
	 	12/23/2004	 	11/018,383	 	U.S.	 	 	 	 	 	5-HT2 receptor binding compounds
	MYOG:049-WO
	 	12/23/2004	 	PCT/US04/042921	 	PCT	 	 	 	 	 	5-HT2 receptor binding compounds
	MYOG:050-US
	 	2/2/2005	 	11/049,630	 	U.S.	 	 	 	 	 	PRK (HDAC kinase II)
	MYOG:050-WO
	 	2/2/2005	 	PCT/US05/002808	 	PCT	 	 	 	 	 	PRK (HDAC kinase II)
	MYOG:054-US
	 	4/5/2005	 	11/099,417	 	U.S.	 	 	 	 	 	Nuclear export
	MYOG:054-WO
	 	4/5/2005	 	PCT/US05/011264	 	PCT	 	 	 	 	 	Nuclear export
	MYOG:057-WO
	 	9/19/2005	 	PCT/US05/033461	 	PCT	 	 	 	 	 	P38 MCIP
	MYOG:058-US
	 	8/15/2005	 	11/203,828	 	U.S.	 	 	 	 	 	Ku
	MYOG:060-USP1
	 	7/13/2005	 	60/699,189	 	U.S.	 	 	 	 	 	Proteasome inhibitors
	MYOG:062-USP1
	 	11/18/2005	 	60/737,952	 	U.S.	 	 	 	 	 	CAMKII/Calpain/HDACs
	UTSD:803-US
	 	5/30/2002	 	10/159,971	 	U.S.	 	6,924,415	 	8/2/2005	 	MEK5
	USTD:803-USD1
	 	4/21/2005	 	11/089,425	 	U.S.	 	 	 	 	 	MEK5
	UTSD:803-CA
	 	5/29/2002	 	2,384,907	 	Canada	 	 	 	 	 	MEK5
	UTSD:803-JP
	 	11/22/2001	 	2001-358595	 	Japan	 	 	 	 	 	MEK5
	USTD:1771-USP1
	 	5/3/2006	 	not yet assigned	 	U.S.	 	 	 	 	 	CAMTA

[..**..] Confidential Treatment Requested

 

 

Schedule 1.31

Myogen Targets

 

[..**..]

[..**..] Confidential Treatment Requested

 

 

Schedule 1.34

List of NIBRI Compounds

Index      Project      Number

[..**..]

 [..**..] Confidential Treatment Requested

 

 

Schedule 8.2

List of Countries Regarding Patent Protection

	 	 	 	 	 
	Albania AL
	 	Algeria DZ	 	Antigua and Barbuda AG
	Argentina
	 	Armenia AM	 	Australia AU
	Austria AT
	 	Azerbaijan AZ	 	Barbados BB
	Belarus BY
	 	Belgium BE	 	Belize BZ
	Benin BJ
	 	Bosnia and Herzegovina BA	 	Botswana BW
	Brazil BR
	 	Bulgaria BG	 	Burkina Faso BF
	Cameroon CM
	 	Canada CA	 	Central African Republic CF
	Chad TD
	 	Chile	 	China CN
	Colombia CO
	 	Congo CG	 	Costa Rica CR
	Côte d’Ivoire CI
	 	Croatia HR	 	Cuba CU
	Cyprus CY
	 	Czech Republic CZ	 	Democratic People's Republic of Korea KP
	Denmark DK
	 	Dominica DM	 	Ecuador EC
	Egypt EG
	 	Equatorial Guinea GQ	 	Estonia EE
	Finland FI 2
	 	France FR	 	Gabon GA
	Gambia GM
	 	Georgia GE	 	Germany DE
	Ghana GH
	 	Greece GR	 	Grenada GD
	Guinea GN
	 	Guinea-Bissau GW	 	Hong Kong
	Hungary HU
	 	Iceland IS	 	India IN
	Indonesia ID
	 	Ireland IE	 	Israel IL
	Italy IT
	 	Japan JP	 	Kazakhstan KZ 1
	Kenya KE
	 	Kyrgyzstan KG	 	Latvia LV
	Lesotho LS
	 	Liberia LR	 	Liechtenstein LI
	Lithuania LT
	 	Luxembourg LU	 	Madagascar MG
	Malawi MW
	 	Malaysia	 	Mali ML
	Mauritania MR
	 	Mexico MX	 	Monaco MC
	Mongolia MN
	 	Morocco MA	 	Mozambique MZ
	Netherlands NL 4
	 	New Zealand NZ	 	Nicaragua NI
	Niger NE
	 	Norway NO	 	Oman OM
	Pakistan
	 	Papua New Guinea PG	 	Peru
	Philippines PH
	 	Poland PL	 	Portugal PT
	Republic of Korea KR
	 	Republic of Moldova MD	 	Romania RO
	Russian Federation RU
	 	Saint Lucia LC	 	Saint Vincent and the Grenadines VC
	Saudi Arabia
	 	Senegal SN	 	Serbia and Montenegro CS
	Seychelles SC
	 	Sierra Leone SL	 	Singapore SG
	Slovakia SK
	 	Slovenia SI	 	South Africa ZA
	Spain ES
	 	Sri Lanka LK	 	Sudan SD
	Swaziland SZ
	 	Sweden SE	 	Switzerland CH
	Syrian Arab Republic SY
	 	Taiwan	 	Tajikistan TJ
	Thailand
	 	The former Yugoslav	 	 
	 
	 	Republic of Macedonia MK	 	Togo TG

 

[..**..] Confidential Treatment Requested

 

	 	 	 	 	 
	Trinidad and Tobago TT
	 	Tunisia TN	 	Turkey TR
	Turkmenistan TM
	 	Uganda UG	 	Ukraine UA
	United Arab Emirates AE
	 	United Kingdom GB	 	United Republic of Tanzania TZ
	United States of America US
	 	Uruguay	 	Uzbekistan UZ
	Venezuela
	 	Viet Nam VN	 	Zambia ZM
	Zimbabwe ZW
	 	 	 	 

 

[..**..] Confidential Treatment Requested

 

Exhibit A-1

Form of License, Development and Commercialization Agreement

 

[Filed Separately as Exhibit 10.40 to the Quarterly Report on Form 10-Q]

[..**..] Confidential Treatment Requested

 

 

Exhibit A-2

Form of HDAC License, Development and Commercialization Agreement

  

[Filed Separately as Exhibit 10.41 to the Quarterly Report on Form 10-Q]

 [..**..] Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]